

1 **Distinguishing science from pseudoscience in commercial respiratory**
2 **interventions: An evidence-based guide for health and exercise**
3 **professionals**

4
5 Camilla R. Illidi¹, Lee M. Romer², Michael A. Johnson³, Neil C. Williams³, Harry B.
6 Rossiter⁴, Richard Casaburi⁴, Nicholas B. Tiller⁴.

7
8 ¹Clinical Exercise and Respiratory Physiology Laboratory, Department of Kinesiology
9 and Physical Education, Faculty of Education, McGill University, Montréal, Quebec,
10 Canada

11 ²Division of Sport, Health and Exercise Sciences, College of Health, Medicine and Life
12 Sciences, Brunel University London, UK.

13 ³Exercise and Health Research Group, Sport, Health and Performance Enhancement
14 (SHAPE) Research Centre, School of Science and Technology, Nottingham Trent
15 University, Nottingham, Nottinghamshire, UK

16 ⁴Institute of Respiratory Medicine and Exercise Physiology, Division of Respiratory and
17 Critical Care Physiology and Medicine, The Lundquist Institute for Biomedical
18 Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.

19
20
21 **Correspondence**

22 Nicholas B. Tiller, Ph.D.

23 1124 W. Carson Street, CDCRC Building, Torrance, CA 90502.

24 Email: nicholas.tiller@lundquist.org | Orchid: <https://orcid.org/0000-0001-8429-658X>

25
26 **Funding Disclosures/conflicts of interest**

27 The authors declare no conflicts of interest and do not have any financial disclosures.

28

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

ABSTRACT

Respiratory function has become a global health priority. Not only is chronic respiratory disease a leading cause of worldwide morbidity and mortality, but the COVID-19 pandemic heightened attention on respiratory health and the means of enhancing it. Subsequently, and inevitably, the respiratory system has become a target of the multi-trillion-dollar health and wellness industry. Numerous commercial, respiratory-related interventions are now on sale, coupled to therapeutic and/or ergogenic claims that vary in their plausibility: from the reasonable to the absurd. Moreover, legitimate and illegitimate claims are often conflated in a wellness space that lacks regulation. The abundance of interventions, the range of potential therapeutic targets in the respiratory system, and the wealth of research that varies in quality, all confound the ability for health and exercise professionals to make informed risk-to-benefit assessments with their patients and clients. This review focuses on numerous commercial interventions that purport to improve respiratory health, including nasal dilators, nasal breathing, generalized and systematized breathing interventions (such as pursed-lips breathing), respiratory muscle training, canned oxygen, various nutritional supplements, and inhaled L-menthol. For each intervention we describe the premise, examine the plausibility, and systematically contrast commercial claims against the published literature. The overarching aim is to assist health and exercise professionals to distinguish science from pseudoscience and make pragmatic and safe risk-to-benefit decisions.

Key words: asthma; COPD; exercise; disease; lung function; nutrition; pulmonary.

51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81

1.0 INTRODUCTION

The human respiratory system comprises the upper respiratory tract (nasal and oral cavities, pharynx, and larynx), lower respiratory tract (trachea, and bronchial tree), lung parenchyma, pulmonary vasculature, and respiratory muscles (e.g., diaphragm, abdominals, obliques, intercostals). Under neural control from central and peripheral chemoreceptors and respiratory centers in the brain, the respiratory system transfers oxygen from the atmosphere to the pulmonary circulation and carbon dioxide in the opposite direction. With a few notable exceptions (e.g., high-intensity exercise, hypoxic environments), the healthy respiratory system is unlikely to present a significant limitation to gas exchange or O₂ transport (Dempsey et al. 2020).

In recent years, the respiratory system has become a target of the multi-trillion-dollar commercial health and wellness industry. Therein, numerous respiratory-related products and strategies (e.g., respiratory muscle training devices, nasal strips, deep breathing regimens) are sold to the consumer alongside therapeutic and/or ergogenic claims that vary in their plausibility: from the reasonable (mitigate stress, improve perceptions, improve lung and respiratory muscle function); to the questionable (increase oxygen transport, “boost” immune function); to the absurd (increase “energy flow” and promote healing). Furthermore, due to lax regulations in the wellness space and little obligation for marketing to conform to scientific or ethical standards, it is common for legitimate and illegitimate claims to be conflated (Tiller et al. 2022). The current ‘wellness’ paradigm thus makes it difficult for health and exercise professionals to make informed risk-to-benefit assessments with their patients and clients.

Several factors underpin the accelerating commercial popularity of respiratory-related interventions, the most pertinent being the COVID-19 pandemic which has heightened attention on respiratory health and potential means of enhancing it. But even before COVID-19, chronic respiratory disease (such as chronic obstructive pulmonary disease [COPD]) was a leading cause of morbidity and mortality (World Health Organization 2022), conferring a considerable and growing economic burden (Ehteshami-Afshar et al. 2016). Respiratory disease has also received growing coverage in the media owing to the pressing issue of climate change and worsening air quality (Barnes et al. 2013). Respiratory function has thus become a global health priority. To

82 compound the problem, respiratory physiology is a complex discipline that is poorly
83 understood by the public, and its mechanisms can thus be easily misappropriated for
84 commercial gain.

85 This review explores a number of commercial interventions that purport to
86 influence aspects of the respiratory system to improve respiratory function, respiratory
87 health, and/or exercise responses. The interventions selected for inclusion were nasal
88 dilators, nasal breathing, generalized and systematized breathing interventions (including
89 pursed-lips breathing), respiratory muscle training, canned oxygen, various nutritional
90 supplements, and inhaled L-menthol. For each intervention we describe its premise,
91 examine its plausibility, and contrast commercial claims against the published literature.
92 The overarching aim of this paper is to provide an evidence-based guide for health and
93 exercise professionals—to help them distinguish science from pseudoscience in
94 respiratory physiology and assist them in making safe and pragmatic risk-to-benefit
95 decisions.

96

97 **1.1 Methods**

98 In January 2022, the first and corresponding authors (CRI and NBT, respectively)
99 convened a meeting of recognized experts in the fields of respiratory medicine and
100 exercise physiology. After several rounds of discussion, all authors agreed that the
101 products/strategies to be included should be non-medical, commercial interventions,
102 excluded if they were controlled drugs and/or regulated by the FDA as “medical devices”.
103 The list was not exhaustive but instead limited to the interventions most prevalent in the
104 health and wellness industry and that were coupled to the most conspicuous claims. A
105 list of commercial claims was then compiled from websites, press releases, and relevant
106 media, after which peer-reviewed articles were searched via PubMed (no date restriction).
107 The literature search-terms comprised the relevant intervention (e.g., nasal dilators,
108 respiratory muscle training, etc.) alongside various combinations of the following:
109 breathlessness; dyspnea; lung; lung function; pulmonary; respiratory; respiratory
110 function; respiratory health; respiratory symptoms; pathophysiology. All article types—
111 meta-analyses, systematic reviews, randomized-controlled trials (RCTs), exploratory
112 studies, confirmatory studies, and case reports—were included, and the reference lists of

113 articles selected for inclusion were manually searched for additional literature. A first draft
114 of the manuscript was collated, and after several rounds of discussion and refinement, all
115 authors agreed upon the evidence summaries and recommendations and approved the
116 final work. Most of the correspondence was carried out virtually/electronically.

117

118

2.0 EVIDENCE REVIEW

2.1 Nasal dilators

120 *2.1.1 Premise and plausibility.* External nasal dilators (ENDs) are applied
121 horizontally to the skin of the nasal dorsum whereas internal nasal dilators (INDs) are
122 placed inside the nostrils. Both purportedly increase nostril patency by preventing the
123 nasal wings from collapsing during inspiration (Dinardi et al. 2014). The devices were
124 originally developed to aid with sleep-related issues (e.g., snoring and apnea) but their
125 widespread use at the Atlanta Olympic Games in 1996 made them popular with
126 exercisers and athletes (Dinardi et al. 2014). Using magnetic resonance imaging, Bishop
127 *et al.* (2016) showed that an END (Breathe Right®) evoked significant enlargement of the
128 anterior nasal passage when compared to a placebo. Using acoustic rhinometry, Griffin
129 *et al.* (1997) observed increased nasal valve area with the same device. Although ENDs
130 had no effect on plethysmography-derived measures of nasal resistance (Vermoen et al.
131 1998) or maximum expiratory flows (Di Somma et al. 1999) in healthy individuals, others
132 have shown that ENDs increased nasal inspiratory flow during normal and forced
133 breathing (Vermoen et al. 1998; Di Somma et al. 1999). Thus, ENDs likely improve nostril
134 patency by supporting the lateral nasal vestibular walls, manifesting as a slight increase
135 in inspiratory nasal flow at rest and during maximal inspiratory maneuvers. The bulk of
136 literature has focused on whether there is any subsequent clinical or ergogenic benefit.

137 *2.1.2 Literature.* Articles were excluded if nasal dilators were simultaneously
138 applied with other breathing interventions. Most studies on nasal dilators evaluated their
139 effect on sleep-related issues including sleep quality, snoring, and obstructive sleep
140 apnea; generally showing subjective (but not objective) outcomes. For example, using
141 ENDs, Wenzel *et al.* (1997) reported improved subjective ratings of nose breathing at rest
142 but no changes in objective (polysomnography-derived) measures of obstructive sleep
143 apnea. Similarly, several non-placebo-controlled studies showed improved subjective
144 ratings of sleep quality (e.g., insomnia severity, sleep-disordered breathing) and quality
145 of life with ENDs (Krakow et al. 2006; Gelardi et al. 2019). When an IND (Nas-Air®) and
146 an END (Breathe Right®) were compared, the former conferred better subjective ratings
147 of sleep quality (assessed via visual analogue scale) (Gelardi et al. 2019). One placebo-
148 controlled study in patients with upper-airway resistance syndrome found that

149 desaturation time during sleep (the percentage of time that SpO₂ was >2% below waking
150 values) was significantly lower with an END (Breathe Right®) versus placebo (9.1 vs.
151 12.2%), but there were no other effects on cardiorespiratory variables, sleep architecture,
152 or sleep latency (Bahammam et al. 1999).

153 Data on snoring are equivocal. Research by Gelardi *et al.* (2019) reported that
154 snoring time was reduced with both an IND and END, whereas Wenzel *et al.* (1997)
155 showed that ENDS had no effect on the frequency of snoring events. When healthy
156 subjects with nasal congestion were randomized to an END group (Breathe Right®) or a
157 placebo group for two weeks, both devices equally improved subjective ratings of sleep
158 quality and subjective ratings of nasal congestion, suggesting a potent placebo effect
159 (Noss et al. 2019). Lastly, Sadan et al. (2005) showed that nasal dilators, when used by
160 females during childbirth, improved subjective ratings of “ease of breathing” but had no
161 effect on objective markers of labor progression or recovery. Collectively, the data
162 suggest that nasal dilators (mainly ENDS) may improve perceptions of nasal breathing
163 and subjective ratings of sleep quality. However, they are unlikely to influence objective
164 markers of obstructive sleep apnea (Camacho et al. 2016) and the data on snoring
165 frequency and duration are equivocal. In fact, several authors have proposed ENDS as
166 an effective placebo intervention in RCTs that explore treatment options in obstructive
167 sleep apnea (Amaro et al. 2012; Yagihara et al. 2017).

168 On the premise that ENDS increase some measures of nasal patency and nasal
169 inspiratory flow, their potential to improve exercise capacity has also been explored.
170 Despite a few reports of favorable outcomes (Griffin et al. 1997; Dinardi et al. 2013, 2017),
171 a recent systematic review and meta-analysis of 19 articles concluded that ENDS elicited
172 “no improvement in $\dot{V}O_{2\max}$, HR and RPE outcomes in healthy individuals during
173 [maximal or submaximal] exercise” (Dinardi et al. 2021). Other studies, using esophageal
174 balloon catheters, report no effect of ENDS on inspiratory elastic work, inspiratory resistive
175 work, or expiratory resistive work during submaximal or maximal exercise (O’Kroy et al.
176 2001). There was also no effect of ENDS on recovery of $\dot{V}O_2$, \dot{V}_E , or HR after exercise
177 when compared to a placebo or a no-intervention control (Thomas et al. 2001); and no
178 effect of ENDS on blood lactate responses after exercise in sedentary or endurance

179 trained women (Boggs et al. 2008). Thus, nasal dilators appear to have no meaningful
180 influence on exercise performance or physiological variables during or after exercise.

181 The commercial claims of one specific IND (Turbine™) have been scrutinized by
182 several studies, all showing no benefit on respiratory mechanics or exercise tolerance.
183 One such study, a sham-controlled trial using esophageal balloon catheters to measure
184 respiratory mechanics during incremental cycling, showed that INDs did not reduce the
185 work of breathing and had no effect on exertional dyspnea or exercise capacity (Schaeffer
186 et al. 2021). Another RCT tested the effect of the Turbine™ on 20-km cycling time-trial
187 performance, reporting no influence on mean power output (Adams and Peiffer 2017).
188 Favorable data from a clinical trial posted on the manufacturer's website have not been
189 peer reviewed or published at the time of this writing.

190 *2.1.3 Evidence Summary and Recommendations.* Primary outcomes from the
191 literature on nasal dilators are summarized in **Figure 1**. Both ENDs and INDs enlarge and
192 stabilize the nasal valves thereby mitigating their collapse during high flow inspiration and
193 increasing inspiratory nasal airflow during maximal inspiratory efforts. Current evidence
194 suggests that nasal dilators may improve perceptions of nasal breathing and subjective
195 ratings of sleep quality but are unlikely to influence objective markers of obstructive sleep
196 apnea. The data on snoring frequency and duration are equivocal. Most studies show no
197 effect of nasal dilators on cardiorespiratory function or ratings of perceived exertion during
198 exercise, no effect on exercise capacity, and no effect on physiological variables during
199 the acute phase of recovery.

200

201 **2.2 Nasal breathing**

202 *2.2.1 Premise and plausibility.* In humans, nitric oxide (NO) is a vasodilator (Morris
203 and Rich 1997) and mild bronchodilator (Kacmarek et al. 1996), first identified in expired
204 gas in the 1990s (Gustafsson et al. 1991). Functionally, the two NO isoforms are
205 “constitutive” and “inducible” NO, with most being produced in the paranasal sinuses
206 (Ricciardolo 2003). In fact, the paranasal sinuses produce considerably greater amounts
207 of NO than either the mouth or the trachea (56 vs. 14 vs. 6 ppb, respectively; (Törnberg
208 et al. 2002)). It has been suggested that nasally-derived NO can evoke airway smooth
209 muscle relaxation, inhibit smooth muscle proliferation, and protect against excessive

210 bronchoconstriction (Ricciardolo 2003). Others suggest that nasal breathing might
211 attenuate pulmonary hypertension by vasodilating the pulmonary vasculature (Settergren
212 et al. 1998). Although exogenous (supplementary) NO is known to reduce vascular
213 resistance and increase pulmonary blood flow in healthy and patient populations
214 (Settergren et al. 1998; Crespo et al. 2010), the concentration of endogenous (nasally-
215 derived) NO is considerably lower than the concentrations used in NO-enriched air
216 (Törnberg et al. 2002). Therefore, an important consideration is whether increased NO
217 uptake via nasal breathing exerts meaningful effects in healthy or patient populations.

218 *2.2.2 Literature.* Articles were excluded if they reported on exogenous
219 (supplementary) NO inhalation as opposed to that which was nasally derived, if they studied
220 exhaled NO as a tool for assessing airway inflammation, or if nasal breathing was studied
221 in combination with other breathing interventions (e.g., deep/slow breathing). Using single
222 photon emission computed tomography during separate bouts of upright nasal or oral
223 breathing in healthy adults, Crespo *et al.* (2010) found that nasal breathing elicited blood
224 flow redistribution from caudal and dorsal regions of the lung to the less-perfused cranial
225 and ventral regions. For the otherwise poorly perfused lung regions, such as the apical
226 region, this represented a 24% increase in blood flow. Similar effects were observed when
227 exogenous NO mixtures were inhaled orally, supporting the hypothesis that the
228 mechanism of blood flow redistribution was mediated by NO. Others showed that nasal
229 breathing increased oxygen tension across the chest wall (assessed using
230 transcutaneous electrodes) in healthy subjects versus oral breathing (Lundberg et al.
231 1996), although the effects were very small and the clinical significance thus unclear.

232 Limited data also suggest a possible therapeutic benefit of nasal breathing in
233 patients with respiratory disease. For example, intubated patients who were unable to
234 rebreathe their own nasally-derived NO exhibited an 18% increase in PaO₂, and an 11%
235 decrease in pulmonary vascular resistance index, when gas derived from the patient's
236 nose was aspirated and fed into the inspiration limb of the ventilator (Lundberg et al.
237 1996). Although the exact mechanism was unclear, the authors postulated that sinus-
238 derived NO may act as an "aerocrine messenger" that selectively dilates vessels
239 supplying well-ventilated areas of the lung. Pulmonary vascular resistance also
240 decreased in patients recovering from thoracic surgery when they engaged in nasal

241 versus oral breathing, although there was no difference in O₂ and CO₂ partial pressures
242 of arterial and mixed venous blood between the two breathing techniques (Settergren et
243 al. 1998). Pertinently, exogenous NO inhaled orally at “nasal physiologic concentrations”
244 of 10–100 ppb evoked pulmonary vasodilatation and improved pulmonary gas exchange
245 in patients with acute respiratory distress syndrome (Mourgeon et al. 1997) and acute
246 respiratory failure (Gerlach et al. 1993). Collectively, these data support the notion that
247 nasal breathing, by increasing NO uptake, may provide clinically meaningful benefits in
248 certain patient populations.

249 The potential benefit of nasal breathing at rest has led to the suggestion that it may
250 improve physiological responses to exercise. However, what of the feasibility of nasal-
251 only breathing during exercise? Healthy adults spontaneously switch from nasal to
252 oronasal breathing at minute ventilations of 35-45 L·min⁻¹ (Niinimaa et al. 1980;
253 Becquemin et al. 1991; Bennett et al. 2003), and without prior habituation, healthy adults
254 even when prompted can only maintain nasal breathing up to ~80% $\dot{V}O_2\text{max}$ (LaComb et
255 al. 2017). Nevertheless, when preceded by an extensive training period (>6 months),
256 nasal breathing may be feasible during high-intensity and even maximal exercise without
257 compromising $\dot{V}O_2\text{max}$ (Hostetter et al. 2016; Dallam et al. 2018). Thus, after habituation,
258 nasal breathing can probably be sustained during maximal exercise. This leads to the
259 separate question of efficacy: does nasal breathing during exercise provide any
260 physiological advantage over oral or oronasal breathing?

261 In a mixed-sex cohort of healthy adults, LaComb *et al.* (2017) showed that nasal
262 breathing elicited lower $\dot{V}O_2$, $\dot{V}CO_2$, and \dot{V}_E at given submaximal exercise intensities
263 (50%, 65%, and 80% of treadmill-derived $\dot{V}O_2\text{max}$) when compared to oral breathing,
264 although the physiological mechanism was unclear. A possible flaw of the study was that
265 exercise bouts lasted only 4 min, whereas a steady state ventilatory response may take
266 considerably longer, particularly in an untrained cohort with a slow kinetic response. The
267 authors also concluded that, when all variables were considered together, “it is likely that
268 oral breathing represents the more efficient mode [of breathing], particularly at higher
269 exercise intensities”. In another study, 10 healthy subjects who were habituated to nasal
270 breathing exhibited lower ventilatory equivalents for O₂ and CO₂ during nasal-only
271 exercise versus oral-only exercise (differences mediated primarily by significantly lower

272 \dot{V}_E), without a change in $\dot{V}O_{2\max}$ or time to exhaustion (Dallam et al. 2018). It is unclear
273 from these studies whether the physiological response to nasal breathing was derived
274 from increased NO uptake or another mechanism. It is possible that healthy subjects will
275 have a blunted ventilatory response at maximal exercise with nasal breathing owing to
276 attenuated tidal volumes and respiratory frequencies (Morton et al. 1995). This may partly
277 explain greater end-tidal CO_2 partial pressure ($P_{ET}CO_2$) during nasal versus oral
278 breathing, both at rest and during submaximal exercise (Tanaka et al. 1988; Dallam et al.
279 2018).

280 Although oral and nasal breathing evoke similar ratings of perceived exertion
281 during exercise, nasal breathing results in an “unacceptable sensation of air hunger”
282 (Hostetter et al. 2016; Dallam et al. 2018), perhaps associated with the development of
283 hypercapnia (Banzett et al. 2021). In turn, this has the potential to alter breathing patterns
284 and reduce exercise tolerance (Dallam et al. 2018). In patients with COPD, who report
285 pre-existing sensations of “unsatisfied inspiration” (Philips et al. 2021), such air hunger
286 during nasal breathing could exacerbate respiratory symptoms. Nasal breathing during
287 exercise would therefore be inappropriate for COPD patients. Two early studies in
288 patients with asthma ($n=5$ and $n=12$, respectively) reported that nasal breathing during
289 exercise reduced the incidence and/or severity of post-exercise bronchoconstriction
290 relative to oral breathing (Shturman-Ellstein et al. 1978; Mangla and Menon 1981),
291 although it is unclear whether these findings were the result of greater NO intake or also
292 influenced by an increased humidity of inspired air which has also been shown to mitigate
293 the severity of exercise-induced bronchoconstriction EIB (Anderson and Kippelen 2012).
294 In any case, these data support the hypothesis that the nasopharynx and oropharynx play
295 an important role in mediating exercise-induced bronchoconstriction.

296 2.2.3 *Evidence Summary and Recommendations.* Primary outcomes from the
297 literature on nasal breathing are summarized in **Figure 2**. Data suggest that nasal
298 breathing may improve arterial oxygenation and ventilatory efficiency in critically ill
299 patients at rest, but there is little evidence that such benefits extend to healthy subjects.
300 Nasal breathing is feasible during submaximal exercise and even maximal exercise after
301 extensive habituation, but there is little-to-no data supporting a subsequent benefit on
302 exercise capacity in healthy individuals. There is some evidence of reduced incidence

303 and/or severity of post-exercise bronchoconstriction with nasal breathing, but due to
304 potential hypoventilation and increased perceptions of “air hunger”, nasal breathing
305 during exercise is not recommended for COPD patients. Its use in patients with other
306 respiratory diseases should be considered on a case-by-case basis.

307

308 **2.3 Generalized and systematized breathing strategies**

309 *2.3.1 Premise and plausibility.* Breathing interventions generally comprise one-or-
310 more of the following techniques: nasal inspiration, deep/slow breathing, breath-hold at
311 end-inspiratory lung volume, prolonged expiration, expiration through pursed lips, and
312 preferential activation of the diaphragm during inspiration. Most breathing interventions
313 encourage inspiration through the nose. This approach may increase the uptake of NO
314 (see Section 2.2) and warm/humidify the inspired air (Naclerio et al. 2007). Inspiration
315 and expiration are usually required to be deep and slow to increase tidal volume and
316 extend the respiratory cycle (Ubolnuar et al. 2019). A prolonged expiration may also help
317 decrease expiratory reserve volume, in turn partially mitigate air trapping and dynamic
318 hyperinflation to reduce respiratory symptoms in certain populations (e.g., COPD).
319 Deep/slow breathing, particularly interventions with prolonged expiration, have also been
320 shown to increase heart rate variability and respiratory sinus arrhythmia through
321 mediating effects on the parasympathetic nervous system (Zaccaro et al. 2018). This is
322 an expanding area of research. Indeed, using functional magnetic resonance imaging,
323 deep/slow breathing was shown to increase cortical and subcortical activity (Critchley et
324 al. 2015), which may partly support improved physical and mental health (Laborde et al.
325 2022). Pursed-lips breathing typically involves nasal inspiration and prolonged expiration
326 directed through lips that have a “puckered” or “pursed” appearance (see **Figure 3**).
327 Independent of other breathing strategies, expiration through pursed lips may increase
328 expiratory resistance at the mouth, evoking a small positive end-expiratory pressure of
329 ~5 cmH₂O (van der Schans et al. 1997). This can help ameliorate airway compression
330 and expiratory flow limitation in patients with COPD by functionally “stenting” the airways
331 (Marciniuk et al. 2011; Nguyen and Duong 2021). Diaphragmatic breathing comprises
332 many of the aforementioned techniques but with preferential activation of the diaphragm
333 during inspiration. From a practical standpoint, diaphragmatic breathing is achieved by

334 inspiring with minimal movement of the chest and more pronounced outward abdominal
335 displacement (Cahalin et al. 2002).

336 2.3.2 *Literature.* The literature on breathing interventions employs inconsistent
337 nomenclature and terms are often used interchangeably. This makes it difficult to discern
338 the efficacy of each technique. Accordingly, we have grouped the literature on breathing
339 interventions and discussed their collective outcomes. The exceptions are pursed-lips
340 breathing (see Section 2.3.3) and the Buteyko Breathing Technique (see Section 2.3.4),
341 which both have a sufficient body of independent research. Most of the literature on
342 breathing interventions has focused on the management of respiratory symptoms in
343 asthma and COPD. Regarding the former, the Cochrane database published a meta-
344 analysis and separate systematic review on breathing exercises in asthmatic adults and
345 children, respectively, with disparate findings. In adults, yoga (including pranayama),
346 breathing retraining, the Buteyko Breathing Technique, the Papworth method, and deep
347 diaphragmatic breathing, all improved quality of life, symptoms and complaints due to
348 hyperventilation, and lung function (forced expiratory volume in 1 second; [FEV₁]).
349 However, studies were characterized by poor methodologies and a very low-to-moderate
350 quality of evidence (Santino et al. 2020). The review in children found insufficient data to
351 support the use of breathing techniques for asthma management, owing primarily to a
352 low number of studies ($n=3$, 112 participants) (Macêdo et al. 2016). Another issue
353 impeding interpretation of the pediatric data is that studies generally combined breathing
354 exercises with a comprehensive package of care, thereby precluding any evaluation of
355 breathing exercises alone (Macêdo et al. 2016). As such, due to a low number of studies,
356 limited reporting of data, and variations in reported outcomes, no firm conclusions can be
357 drawn regarding the efficacy of breathing interventions for asthma management. More
358 well-controlled, high-quality studies are needed.

359 There is a much larger body of work evaluating breathing interventions for
360 improving respiratory symptoms, lung function, and exercise performance and capacity
361 in COPD. In general, long-term breathing interventions including deep breathing with or
362 without preferential activation of the diaphragm, pursed-lips breathing, yoga, singing, and
363 breathing gymnastics, all appear to improve functional exercise performance (mainly 6-
364 min walk test; [6MWT]) (Hamasaki 2020; Lu et al. 2020; Yang et al. 2022), quality of life

365 (St. George's Respiratory Questionnaire; (Marotta et al. 2020) and stress and anxiety
366 (Hamasaki 2020) in COPD. Several studies also show that pursed-lips breathing, with or
367 without preferential activation of the diaphragm, improves pulmonary function (i.e., forced
368 vital capacity [FVC] and FEV₁) (Hamasaki 2020; Lu et al. 2020; see Yang et al. 2022).

369 The literature on breathing interventions for improving dyspnea in COPD is less
370 consistent. A review of 13 RCTs (998 patients) found that home-based breathing
371 exercises (diaphragmatic breathing, yoga breathing, breathing gymnastics, and singing)
372 improved resting FEV₁, 6MWT distance, and ratings of dyspnea (modified Medical
373 Research Council dyspnea scale and St George Respiratory Questionnaire) across the
374 range of disease severity (Lu et al. 2020). By contrast, a Cochrane review of 16 studies
375 (1,233 patients) showed that 15 weeks of breathing retraining (pursed-lips breathing,
376 diaphragmatic breathing, ventilation feedback training, or yoga breathing, both
377 supervised and unsupervised) improved 6MWT distance in COPD but had no consistent
378 effects on dyspnea at rest or health-related quality of life (Holland et al. 2012). Another
379 systematic review and meta-analysis of 19 studies (745 patients) reported that respiratory
380 frequency was significantly reduced at rest and during exercise following a period of
381 dedicated pursed-lips breathing, ventilatory feedback and exercise, diaphragmatic
382 breathing, or combined techniques that lasted between one day and 24 weeks—
383 nevertheless, breathing interventions did not improve ratings of dyspnea relative to
384 controls (Ubolnuar et al. 2019). The reason for the discrepancy in dyspnea-related
385 findings is unclear; however, while Holland *et al.* (2012) and Ubolnuar *et al.* (2019)
386 included studies performed in various environments (including the laboratory and during
387 pulmonary rehabilitation programs in outpatient settings), the review by (Lu et al. 2020)
388 focused exclusively on home-based breathing interventions.

389 *2.3.3 Pursed-lips breathing (PLB).* This particular technique has received a great
390 deal of attention as a standalone therapy owing to its effects on dyspnea and exercise
391 tolerance in patients with COPD. The main benefits include reduced respiratory
392 frequency, increased (improved) inspiratory and total respiratory time, and increased tidal
393 volume (Ubolnuar et al. 2019). A bout of PLB has also been shown to reduce resting CO₂
394 retention and increase arterial oxygen tension and oxyhemoglobin saturation in advanced
395 but stable COPD (Thoman et al. 1966; Breslin 1992; Marciniuk et al. 2011). The primary

396 mechanism by which PLB exerts its effects is by increasing intraluminal airway pressure
397 during exhalation which tends to prevent the airway compression that would otherwise
398 occur as intrapleural pressure increases. In turn, PLB is likely to ameliorate air trapping.
399 Since PLB reduces end-expiratory lung volume and lengthens the diaphragm (thereby
400 improving its tension-generating capacity during inspiration) (Spahija et al. 2005),
401 increased arterial oxygen saturation is likely the result of a more complete, mechanically-
402 efficient respiratory cycle. Pursed-lips breathing has also been used by COPD patients
403 during exercise, with generally favorable outcomes on 6MWT (Bhatt et al. 2013), perhaps
404 mediated by reduced dynamic lung hyperinflation (Cabral et al. 2015), increased arterial
405 oxygen saturation (Cabral et al. 2015), and possible protection against diaphragmatic
406 fatigue (Breslin 1992). Notwithstanding, improvements in exercise capacity with PLB are
407 not a universal finding (Garrod et al. 2005).

408 Several studies in patients with COPD have tried to distinguish the benefits of PLB
409 from other respiratory interventions or relaxation techniques. Pivotal research by Tiep *et*
410 *al.* (1986) showed that an acute (15-min) bout of PLB evoked greater increases in SpO₂
411 at rest compared with general relaxation techniques. Others have found that 12 weeks of
412 daily PLB practice was more effective at reducing exertional dyspnea, and increasing
413 6MWT performance, than expiratory muscle training or a control group that received an
414 educational pamphlet but no intervention (Nield et al. 2007). In another study, a 12-week
415 PLB intervention increased FEV₁ and maximal inspiratory pressures by a greater
416 magnitude than diaphragmatic breathing or a no-intervention control (Jansang et al.
417 2016). One study assessed the effects of an acute bout of diaphragmatic breathing with
418 or without PLB on COPD patients during upright, seated rest (Mendes et al. 2019).
419 Although both interventions increased ribcage and abdominal volumes (measured via
420 respiratory inductive plethysmography), increased arterial oxygen saturation, and
421 decreased respiratory frequency, there were greater reductions in respiratory frequency
422 and longer expiratory times with combined diaphragmatic and pursed-lips breathing.
423 Conversely, neither intervention reduced dyspnea (Medical research Council scale) or
424 end-expiratory chest volume. Thus, the combination of breath control (with preferential
425 activation of the diaphragm) and prolonged expiration through pursed lips may provide
426 several benefits that are distinct from other breathing techniques. Indeed, as an effective

427 means of managing dyspnea in COPD, PLB has been advocated by the Canadian
428 Thoracic Society in their clinical practice guidelines (Marciniuk et al. 2011) and by the
429 American Thoracic Society in their patient education materials (Lareau et al. 2020).

430 2.3.4 *The Buteyko Breathing Technique.* This (predominantly) commercial
431 breathing regimen was conceived in the 1950s by Dr Konstantin Pavlovic Buteyko. In its
432 modern form, Buteyko is an amalgam of several breathing techniques which emphasize
433 nasal breathing and periods of breath-hold (referred to as “control pause”). In general, the
434 research on Buteyko is favorable, particularly with respect to asthma management,
435 showing improved quality of life scores (Burgess et al. 2011; Santino et al. 2020).
436 Nevertheless, Buteyko breathing does not appear to be superior to other chronic
437 breathing interventions like yoga, deep/slow breathing, pursed-lips breathing, or
438 diaphragmatic breathing. In addition, several issues cloud the interpretation of the
439 Buteyko literature, potentially undermining its validity.

440 First, Buteyko breathing is usually administered as a comprehensive package of
441 care that comprises breathing retraining, education, and nutritional advice, making it
442 difficult to discern the isolated benefits of the respiratory intervention (Bruton and Lewith
443 2005). Second, proponents of Buteyko breathing often extend the claims beyond those
444 supported by the scientific literature. For instance, a major premise of the technique is
445 that breath-hold time predicts alveolar CO₂ according to a patented mathematical
446 formula—a claim that has been empirically disproven (Courtney and Cohen 2008). The
447 Buteyko technique also advocates mouth taping as a means of obligating nasal breathing
448 during sleep. However, a randomized, crossover study in patients with symptomatic
449 asthma showed that mouth taping had no effect on asthma control (Cooper et al. 2009).
450 Some proponents even suggest, without evidence, that Buteyko breathing can treat
451 diseases and symptoms (including diabetes, attention-deficit hyperactive disorder, and
452 dental health), claims which undermine the scientific legitimacy of the intervention. It is
453 also worth noting that most clinical studies on Buteyko have assessed outcomes in
454 response to physiotherapy programs that tend to focus on the more conventional,
455 evidence-based aspects of the technique (e.g., deep breathing through the nose).

456 Another approach of some Buteyko proponents is to associate the technique with
457 unrelated, or tenuously related, research. For example, studies have identified a high

458 prevalence of allergic rhinitis in children with ADHD (Brawley et al. 2004). By promoting
459 nasal breathing, Buteyko breathing advocates thus imply that the technique can reduce
460 the risk of developing ADHD. Lastly, several commercial incarnations of Buteyko promote
461 long breath holds (>25 s) which may be unsuitable for certain groups (e.g., COPD
462 patients). Accordingly, while the more conventional aspects of Buteyko breathing (nasal
463 inspiration, deep/slow breathing, and breath training) may have benefits for respiratory
464 function, health and exercise professionals should be wary of those claims that are
465 lacking plausibility, currently unproven, and potentially dangerous.

466 *2.3.5 Additional considerations and conclusions on respiratory interventions.* The
467 literature on breathing techniques for patients with respiratory disease is generally
468 positive. Still, there are subtle nuances in the data that should be highlighted prior to
469 interpretation. For example, research suggests that respiratory physiotherapy using
470 breathing training has the potential to improve inspiratory and expiratory muscle strength
471 following *upper* abdominal surgery (Grams et al. 2012), yet this has questionable utility
472 following *general* abdominal surgery (Pasquina et al. 2006). Physicians and other
473 healthcare professionals must also be conscious of instances where breathing training
474 may be less favorable or even harmful to their patients. Respiratory physiotherapy seems
475 to have limited benefit on lung volume or mortality risk following lung resection (Larsen et
476 al. 2020), and PLB specifically has been shown to increase metabolic demands in
477 patients with interstitial lung disease (Parisien-La Salle et al. 2019). This brings into
478 question the efficacy of PLB for restrictive disorders. Certain breathing techniques may
479 also worsen respiratory symptoms; e.g., several studies show that diaphragmatic
480 breathing may exacerbate dyspnea in patients with severe COPD (Hamasaki 2020),
481 perhaps due to negative effects on the work of breathing and its mechanical efficiency
482 (Gosselink et al. 2012). Anecdotally, the technical demands of preferentially activating the
483 diaphragm during inspiration may render such interventions unsuitable for respiratory
484 patients.

485 *2.3.6 Evidence Summary and Recommendations.* Primary outcomes from the
486 literature on breathing interventions are summarized in **Figure 3**. Breathing interventions
487 such as deep breathing and pursed-lips breathing may elicit favorable changes in tidal
488 volume, respiratory frequency, respiratory time, and arterial oxygen saturation in patients

489 with COPD, particularly those with severe or very severe disease. Long-term breathing
490 retraining strategies may improve lung function (mainly lung volumes and capacities),
491 exercise performance, respiratory symptoms, and quality of life in respiratory patients.
492 Pursed-lips breathing, in particular, is an important standalone therapy that should be
493 considered as an adjunct to exercise training and pharmaceutical interventions in
494 pulmonary rehabilitation programs. Breathing interventions should emphasize a deep and
495 slow nasal inspiration followed by a slow and prolonged expiration through pursed lips.
496 Because of possible negative outcomes in patients, breathing interventions should be
497 delivered by experienced therapists with a comprehensive understanding of the benefits
498 and risks of each technique. Patients must also be managed on a case-by-case basis.
499 The benefits of deep/slow breathing in healthy subjects (with normal pulmonary function)
500 are likely limited to changes in parasympathetic activity (and thus heart rate variability)
501 which may support emotional wellbeing rather than other aspects of cardiopulmonary
502 function.

503

504 **2.4 Respiratory muscle training**

505 *2.4.1 Premise and plausibility.* The healthy respiratory system has typically been
506 considered “overbuilt” for the ventilatory demands placed upon it during strenuous
507 exercise. More recently, however, studies have revealed several respiratory constraints
508 that may impede exercise performance in healthy subjects, particularly those who are
509 endurance-trained, and in certain patients with cardiorespiratory disease (Dempsey et al.
510 2020). When breathing frequency increases during exercise, there is a consequent
511 increase in the resistive loads placed upon the inspiratory and expiratory muscles. In
512 patients with COPD, the resistive loads are exacerbated due to narrowing of peripheral
513 airways. In addition, at lung volumes above relaxation volume, where lung and chest wall
514 compliance are reduced, the inspiratory muscles must overcome increased elastic recoil
515 forces. This increase in elastic loading occurs when tidal volume increases with exercise,
516 and especially in the presence of dynamic lung hyperinflation (i.e., increase in end-
517 expiratory lung volume) consequent to the dynamic compression of airways during forced
518 expiration. Airway narrowing and loss of elastic recoil in COPD give rise to static lung
519 hyperinflation, which further increases the elastic loading on the inspiratory muscles. In

520 severe COPD, incomplete expiration and inward recoil of the lungs and chest wall result
521 in progressive air trapping and increased alveolar pressure at the end of expiration (i.e.,
522 intrinsic positive end-expiratory pressure, PEEPi). To initiate inspiratory airflow, the
523 inspiratory muscles must generate a negative pressure equal in magnitude to PEEPi,
524 subsequently imposing a threshold load on the inspiratory muscles. When the lung is
525 acutely inflated, the pressure-generating capacity of the diaphragm is impaired because
526 the muscle is shortened. At high lung volumes, the pressure-generating capacity of the
527 diaphragm may be further reduced by an increased radius of muscle curvature. Lung
528 inflation also impairs the pressure-generating capacity of the inspiratory intercostal
529 muscles (external intercostals and parasternal intercostals); in contrast to the diaphragm,
530 however, this impairment has been ascribed to changes in the orientation and motion of
531 the ribs (De Troyer and Wilson 2009). In COPD, reductions in the pressure-generating
532 capacity of respiratory muscles may also result from disease-induced changes in
533 respiratory muscle morphology.

534 Increased loading of the respiratory muscles and/or decreased capacity of the
535 respiratory muscles for pressure generation have direct functional consequences. For
536 instance, an increase in the respiratory muscle load/capacity ratio contributes significantly
537 to the subjective experience of breathing discomfort (i.e., dyspnea) (McConnell and
538 Romer 2004a) and predisposes the respiratory muscles to fatigue. Regarding the latter,
539 decreases in the contractile function of inspiratory and expiratory muscles have been
540 noted following intense, whole-body exercise in healthy young adults (Johnson et al.
541 1993; Taylor et al. 2006; Tiller et al. 2017) and in select patients with COPD (Hopkinson
542 et al. 2010; Bachasson et al. 2013). This exercise-induced decrease in respiratory muscle
543 capacity further increases the subjective experience of dyspnea. Moreover, the
544 metabolite accumulation associated with fatiguing respiratory muscle work can elicit a
545 sympathetically-mediated vasoconstrictor response in locomotor muscles. This so-called
546 'respiratory muscle metaboreflex' may decrease locomotor muscle blood flow in favor of
547 an increase in blood flow to the respiratory muscles, thereby increasing the fatigability of
548 limb locomotor muscles and reducing central motor output via feedback effects (Sheel et
549 al. 2018). In COPD, excessive loading of the respiratory muscles and activation of the

550 respiratory muscle metaboreflex may partly contribute to the early development of limb
551 muscle fatigue (Amann et al. 2010).

552 Respiratory muscle training (RMT) was developed on the premise that enhancing
553 the pressure-generating capacity of respiratory muscles would increase fatigue
554 resistance and/or mechanical efficiency of the respiratory muscles during exercise. Such
555 changes would be expected to prevent or delay the respiratory muscle metaboreflex,
556 thereby improving O₂ delivery to working limbs and reducing the intensity of perceived
557 limb discomfort (see **Figure 4**). An increase in the pressure-generating capacity of the
558 respiratory muscles with targeted training would also be expected to reduce the intensity
559 of perceived dyspnea. In health, RMT has been shown to improve the static and dynamic
560 function of respiratory muscles (Romer and McConnell 2003), attenuate fatigability of
561 respiratory (Verges et al. 2007, 2009) and locomotor muscles (McConnell and Lomax
562 2006), blunt the respiratory muscle metaboreflex (Witt et al. 2007), and attenuate
563 perceptions of respiratory and limb discomfort (McConnell and Romer 2004a). Research
564 pertaining to the influence of RMT on whole-body exercise performance in athletes and
565 patients is somewhat contradictory (see *Literature*).

566 The three most common approaches to RMT involve flow-resistive loading (high
567 pressure, low flow), pressure-threshold loading (high pressure, moderate flow), and
568 isocapnic voluntary hyperpnea (low pressure, high flow). Devices that impose a resistive
569 or threshold load elicit improvements predominately in respiratory muscle strength,
570 whereas isocapnic voluntary hyperpnea elicits improvements predominantly in respiratory
571 muscle endurance (see McConnell and Romer 2004b for review). More recently, a
572 tapered flow-resistive loading device has been developed to produce a variable load that
573 matches the pressure-volume relationship of inspiratory muscles (Langer et al. 2013). A
574 recent development in the RMT literature pertains to external loading of the respiratory
575 muscles *during* exercise (in-task). So-called “functional” RMT typically involves flow-
576 resistive loading via facemask (Porcari et al. 2016)¹ or nasal restriction (Arnedillo et al.
577 2020; Gonzalez-Montesinos et al. 2021). Although functional RMT is an attractive
578 proposition due to its specificity of application, the additional loads imposed on the
579 respiratory muscles, and hence the potential training stimulus, are difficult to quantify.

580 From a practical standpoint, functional RMT may limit the physiological stimulus that can
581 be obtained by applying RMT and exercise independently (Faghy et al. 2021).

582 *2.4.2 Literature.* In 1976, Leith and Bradley showed that the respiratory muscles of
583 healthy individuals could be trained to increase strength or endurance. Later research
584 sought to evaluate the efficacy of RMT with respect to whole-body exercise performance
585 in healthy individuals and in patients with respiratory disease. Unfortunately, many of the
586 early studies were hampered by methodological shortcomings, including small sample
587 sizes, absence of sham-control groups, unbalanced baseline characteristics, inadequate
588 training intensities, and inappropriate outcome measures (McConnell and Romer 2004b).
589 As such, the ergogenic effect of RMT has been the subject of much debate (e.g.,
590 McConnell 2012; Patel et al. 2012). A systematic review and meta-analysis of 46 studies
591 on the effects of RMT in healthy individuals revealed an improvement in endurance
592 performance as assessed using fixed-intensity tests, simulated time-trials, and
593 intermittent incremental tests (Illi et al. 2012). The analysis also showed that
594 resistive/threshold and hyperpnea training did not differ in their effects, that combined
595 inspiratory/expiratory strength training tended to be superior to either intervention alone,
596 and that the greatest improvements with RMT occurred in less-fit subjects and in sports
597 of longer duration (Illi et al. 2012). Another systematic review and meta-analysis, this time
598 on responses in athletes, showed a positive effect of RMT on respiratory muscle function
599 and sport performance outcomes (HajBhanbari et al. 2013). Although the report also
600 noted comparable benefits of RMT for “elite” and “recreational athletes”, the authors
601 classified trained status by whether the subject’s $\dot{V}O_2\text{max}$ was above or below the
602 minimum, pre-determined requirements for being considered an “athlete”, but without
603 specifically defining “elite”. Thus, the question as to whether training status mediates the
604 efficacy of RMT remains unresolved. More recent studies have shown improvements in
605 repeated-sprint performance (e.g., shorter recovery between sprints or increased number
606 of repetitions) as well as reduced effort perceptions and markers of metabolic stress after
607 resistive RMT (Lorca-Santiago et al. 2020). Collectively, the data show an ergogenic
608 effect of RMT on endurance and repeated-sprint performance in healthy individuals.

609 The efficacy of RMT in patients with COPD has been studied extensively. While
610 whole-body exercise training is a crucial component of pulmonary rehabilitation in this

611 population (Casaburi 2008), exercise training does not appear to increase the pressure-
612 generating capacity of the respiratory muscles. Consequently, there has been a great
613 deal of interest in the potential for RMT to increase the capacity of the respiratory muscles
614 and alleviate symptoms. Learned societies, including the American College of Chest
615 Physicians/American Association of Cardiovascular and Pulmonary Rehabilitation (Ries
616 et al. 2007) and the European Respiratory Society/American Thoracic Society (Spruit et
617 al. 2013), have recommended RMT for patients who, despite optimal medical therapy,
618 exhibit dyspnea and reduced respiratory muscle strength. Several systematic reviews and
619 meta-analyses have shown that RMT, when applied as a standalone intervention with
620 controlled training loads in patients with COPD, improves respiratory muscle strength and
621 endurance, exercise capacity, dyspnea, and health-related quality of life (e.g., Gosselink
622 et al. 2011). Adding RMT to a whole-body exercise training program in COPD was shown
623 to have no additive effects on exercise performance or quality of life, suggesting that RMT
624 may only be effective as a standalone treatment in the absence of other interventions
625 (e.g., Gosselink et al. 2011). This notion is corroborated by a recent systematic review
626 and meta-analysis which showed that inspiratory pressure-threshold training in patients
627 with COPD increased inspiratory muscle strength, functional exercise performance, and
628 dyspnea during activities of daily living, but with no additional effect on the intensity of
629 exertional dyspnea when used as an adjunct to pulmonary rehabilitation (Beaumont et al.
630 2018a). Notwithstanding the limitations of meta-analyses (e.g., poor quality of included
631 studies, heterogeneity, publication bias), recent large-scale RCTs on the effects of RMT
632 in patients with COPD have confirmed that improvements in inspiratory muscle function
633 after adjunctive RMT do not translate to additional improvements in functional exercise
634 capacity, dyspnea, or quality of life (Beaumont et al. 2018b; Schultz et al. 2018;
635 Charususin et al. 2018a). In patients with inspiratory muscle weakness, however,
636 adjunctive RMT during a whole-body exercise training intervention elicited a significant
637 increase in endurance cycling time and a significant reduction in dyspnea intensity at iso-
638 time during the cycling test compared to sham-training (Charususin et al. 2018b).

639 *2.4.3 Additional applications and population subgroups.* While most studies have
640 investigated the influence of RMT on exercise outcomes in healthy individuals (athletes
641 and non-athletes) and patients with COPD, RMT may also have an application in other

642 settings where the loads imposed on the respiratory muscles are elevated or the capacity
643 to generate force is reduced. For instance, RMT has been considered in the context of
644 environmental and occupational settings (e.g., altitude and load carriage) (Faghy and
645 Brown 2015; Chambault et al. 2021), and studied in the context of natural aging (Seixas
646 et al. 2020; Manifold et al. 2021). In older adults, exertional dyspnea is consistently
647 elevated at any given intensity of submaximal exercise owing to an increased ventilatory
648 demand (Jensen et al. 2009). Conceivably, RMT might improve exertional dyspnea in
649 older adults through a reduction in the load/capacity ratio of respiratory muscles. In
650 addition to the increase in ventilatory demand, aging is accompanied by a decline in
651 respiratory muscle function which, through a reduction in postural control, has been
652 shown to correlate with impairments in balance performance (Rodrigues et al. 2020). In
653 turn, RMT has been shown to improve balance performance through an increase in the
654 neuromuscular activity of postural muscles (Ferraro et al. 2019, 2020, 2022; Tounsi et al.
655 2021).

656 Recent evidence indicates that females have smaller airways than males, and
657 subsequently exhibit greater flow-resistive work of breathing (Peters et al. 2021). There
658 also appears to be a combined influence of age and biological sex on respiratory
659 mechanics which contributes in part to the increased perception of exertional dyspnea
660 noted in older women (Molgat-Seon et al. 2018). Thus, RMT could be an effective
661 intervention to enhance the overall exercise response in young and older women. Other
662 groups with imbalances in the load/capacity ratio of respiratory muscles, and which might
663 therefore benefit from RMT, include: exercise-induced laryngeal obstruction (Sandnes et
664 al. 2022), obstructive sleep apnea (Torres-Castro et al. 2022), cystic fibrosis (Stanford et
665 al. 2020), interstitial lung disease (Zaki et al. 2022), stroke (Fabero-Garrido et al. 2022),
666 hypertension (Craighead et al. 2022), chronic heart failure (Azambuja et al. 2020),
667 pulmonary hypertension (Tran et al. 2021), neurological disorders (He et al. 2021), spinal
668 cord injury (Woods et al. 2022), pre-operative surgery (Dsouza et al. 2021), weaning from
669 mechanical ventilation (Worrapphan et al. 2020), ventilator-induced diaphragm dysfunction
670 in the recovery phase (Ahmed et al. 2019), and COVID-19 (e.g., risk reduction, ICU,
671 recovery, and long-COVID) (McNarry et al. 2022). Evidence of the efficacy of RMT in
672 these groups requires further prospective study.

673 *2.4.4 Evidence summary and recommendations.* Primary outcomes from the
674 literature on RMT are summarized in **Figure 4**. If applied with the appropriate frequency,
675 intensity, and duration, RMT can improve specific aspects of respiratory muscle function
676 (e.g., strength and endurance). There is convincing evidence of an ergogenic effect of
677 RMT in healthy individuals (athletes and non-athletes). As a standalone therapy, RMT
678 confers multiple benefits for select patients with COPD. However, the effect of adding
679 RMT to a general exercise program in COPD (including during pulmonary rehabilitation)
680 appears limited. It is conceivable that RMT may be useful for patients with respiratory
681 muscle weakness or those with pre-existing comorbidities who are unable to participate
682 in whole-body exercise training. Further RCTs are needed to ascertain which patients
683 and groups are likely to benefit from RMT.

684

685 **2.5 Canned oxygen**

686 *2.5.1 Premise and plausibility.* Commercial canned oxygen (intended for non-
687 medical use) is a can of hyperoxic gas (~95% O₂) equipped with a mask or inhaler cap.
688 The suggested protocol for use differs among manufacturers but typically involves several
689 inhalations, repeated 8-10 times, periodically throughout the day or as needed. Some
690 vendors recommend their product for use immediately before physical activity and/or
691 sporting competition. The ergogenic claims include improved reaction time, “improved
692 breathing” during exposure to heat and pollution, and improved sports performance by
693 delaying onset of fatigue and improving O₂ availability for oxidative metabolism. Some
694 brands combine eucalyptus and other oils with the gas mixture which they claim can “relax
695 the nervous system, relax the muscles, and relieve stress”. Despite the extensive claims
696 and widespread and costly prescription of so-called “short burst oxygen therapy” for
697 respiratory patients (e.g., COPD), there is no clear mechanism for the purported
698 physiological benefit. Moreover, in healthy individuals, hemoglobin remains nearly
699 completely saturated with O₂ at rest, and exercise-induced arterial O₂ desaturation (i.e.,
700 hypoxemia) rarely occurs in healthy (untrained) individuals at sea-level. Consequently,
701 there is little plausibility that acute exposure to concentrated O₂ (i.e., several breaths) will
702 influence respiratory outcomes or exercise performance.

703 *2.5.3 Literature.* The focus of this section is on commercially available canned
704 oxygen and “short burst oxygen” rather than physician-prescribed supplemental oxygen
705 therapy. A systematic review on the efficacy of short-burst oxygen to improve
706 breathlessness, exercise capacity, arterial oxygen saturation, and ventilatory variables in
707 patients with COPD, concluded that its widespread prescription was not evidence-based
708 (O’Neill et al. 2006). Due to a lack of peer-reviewed studies on commercial canned oxygen
709 in particular, most vendors cite clinical literature that is tenuously related (e.g., studies on
710 hyperbaric oxygen therapy or prolonged inhalation of medically certified gas mixtures).
711 Thus, the references provided by manufacturers do not support the claims. One
712 manufacturer published an online press release that mimicked the appearance of a
713 scientific journal article (Elizondo et al. 2019), presumably in an effort to feign scientific
714 legitimacy. On the rare occasion that relevant journal articles were obtained through
715 commercial websites, they were of very low quality and exhibited a high risk of bias. It is
716 worth noting that although gaseous supplemental oxygen (delivered by inhalation) is not
717 prohibited by the World Anti-Doping Agency (WADA 2022), some sports authorities
718 prohibit its use. Athletes should therefore be cognizant of the rules and regulations
719 regarding O₂ therapy that govern their sport.

720 *2.5.4 Evidence Summary and recommendations.* The proposed benefit of acute
721 inhalation of canned oxygen has low plausibility and there is no valid evidence of
722 beneficial effects.

723

724 **2.6 Nutritional interventions**

725 *2.6.1 Premise & plausibility.* Nutrition is a modifiable factor that influences the
726 development and progression of many non-communicable diseases (Cena and Calder
727 2020; Dominguez et al. 2021). Some nutrients have immunomodulatory, anti-
728 inflammatory, and/or antioxidant effects (Kau et al. 2011; Venter et al. 2020; Gozzi-Silva
729 et al. 2021). Such nutrients may therefore influence respiratory health and disease
730 risk/progression in conditions underpinned by airway and/or systemic inflammation
731 (Berthon and Wood 2015; Hosseini et al. 2017; Parvizian et al. 2020; Heloneida de Araújo
732 Morais et al. 2021). In addition, supplementation with certain nutrients may provide
733 prophylactic and/or therapeutic benefits for certain respiratory patients.

734 In terms of therapeutic benefits on respiratory health, the bulk of literature focuses
735 on vitamin D, various antioxidants (most commonly vitamin C), omega-3 polyunsaturated
736 fatty acids (n-3 PUFAs), probiotics, and prebiotics. The wealth of literature precludes any
737 detailed discussion of the complex and diverse mechanisms underpinning each nutrient
738 and their independent effects on respiratory health. Instead, the following summary
739 focuses on empirical data regarding the purported antioxidant and immunomodulatory
740 effects and whether they translate to clinically meaningful outcomes.

741 *2.6.2. Literature on Vitamin D₃.* Circulating concentrations of 25(OH)D—a form of
742 vitamin D produced in the liver from hydroxylation of vitamin D₃—were found to be
743 inversely associated with the incidence of upper- and/or lower-respiratory tract infection
744 (RTI) (Pham et al. 2019). The incidence of RTI in the general population peaks in the
745 winter (Ginde et al. 2009) when vitamin D deficiency is most common owing to low skin
746 exposure to sunlight ultraviolet B radiation (Farrokhyar et al. 2014; Cashman et al. 2016).
747 Indeed, insufficient circulating concentrations of vitamin D (baseline serum 25(OH)D <50
748 nmol·L⁻¹) have been observed in military personnel (Harrison et al. 2021), athletes
749 (Farrokhyar et al. 2014), and healthy controls (Cashman et al. 2016).

750 Vitamin D sufficiency can be achieved via oral vitamin D₃ supplementation
751 (Carswell et al. 2018; Harrison et al. 2021) and safe exposure to sunlight or simulated
752 sunlight. However, evidence of prophylactic and/or therapeutic effects of vitamin D₃
753 supplementation is confounded by heterogeneity across trials (Jolliffe et al. 2021), with
754 effect-modifiers including dosing regimen and duration, participant age, baseline
755 25(OH)D, and geographic location (Martineau et al. 2017; Vlieg-Boerstra et al. 2021;
756 Jolliffe et al. 2021; Cho et al. 2022). A recent meta-analysis of 43 RCTs ($n = 48,488$
757 mixed-health cohort of children and adults) revealed a modest but overall decreased risk
758 of acute respiratory infection with daily vitamin D₃ supplementation of 400-1000 IU·d⁻¹
759 (Jolliffe et al. 2021). A recent RCT reported no change in the incidence of upper-
760 respiratory tract infection following 12 weeks of vitamin D₃ supplementation (1,000 IU·d⁻¹
761 for the first four weeks and 400 IU·d⁻¹ for eight weeks), but found decreased peak severity
762 and duration of illness (Harrison et al. 2021). Accordingly, irrespective of whether vitamin
763 D₃ supplementation influences the incidence of upper-RTI, it may still attenuate the
764 severity and/or duration of illness.

765 There is a high prevalence of vitamin D deficiency in patients with asthma (Bener
766 et al. 2014) and COPD (Janssens et al. 2011). In fact, in these patients, higher vitamin D
767 concentrations are associated with lower risk, severity, and exacerbation of the primary
768 disease (Gupta et al. 2011; Zhu et al. 2016; Liu et al. 2019). Vitamin D supplementation
769 in these groups has thus been studied for its prophylactic and therapeutic effects. There
770 is insufficient evidence that the prophylactic use of vitamin D₃ can prevent asthma in
771 children (Yepes-Nuñez et al. 2018; Luo et al. 2022). In addition, the association between
772 vitamin D status and adult-onset asthma is unclear (Mai et al. 2012; Cheng et al. 2014;
773 Confino-Cohen et al. 2014; Cherrie et al. 2017; Manousaki et al. 2017). The therapeutic
774 effects of vitamin D₃ supplementation in children and adults with pre-existing asthma are
775 also equivocal (Jolliffe et al. 2021; Chen et al. 2021). For instance, a recent systematic
776 review (Nitzan et al. 2022) and an independent meta-analysis (Kumar et al. 2021) both
777 concluded that vitamin D₃ supplementation did not affect lung function, asthma control,
778 or exacerbation rates in children. Although these studies were not performed in children
779 with pre-existing vitamin D deficiency, findings generally concur with recent RCTs in
780 children with 25(OH)D concentration <50 nmol·L⁻¹ (Jat et al. 2021) and <75 nmol·L⁻¹
781 (Forno et al. 2020; Han et al. 2021). By contrast, in asthmatic adults with low vitamin D₃
782 concentration, a meta-analysis of three small trials (*n* = 92) revealed some protection of
783 vitamin D₃ supplementation against exacerbations (Jolliffe et al. 2017). One RCT also
784 showed improved asthma control in 25(OH)D-deficient adults who were supplemented
785 with a weekly dose of 16,000 IU (Andújar-Espinosa et al. 2021).

786 Based on the aforementioned evidence, vitamin D₃ supplementation does not
787 improve lung function in COPD patients (Lehouck et al. 2012; Sluyter et al. 2017; Chen
788 et al. 2019; Foumani et al. 2019), although it may confer improvements in FEV₁ in current
789 or former smokers with 25(OH)D <50 nmol·L⁻¹ (Sluyter et al. 2017). Data from one meta-
790 analysis of four RCTs (*n*=560) indicate that vitamin D₃ supplementation reduces
791 exacerbation rates in vitamin D-deficient patients (Jolliffe et al. 2019). Thus, for COPD
792 patients who are hospitalized for exacerbation, the Global Initiative for Chronic
793 Obstructive Lung Disease recommends vitamin D screening and subsequent
794 supplementation for those found to be deficient (Global Initiative for Chronic Obstructive
795 Lung Disease, 2022).

796 2.6.3 *Literature on Vitamin C*. In healthy populations, the efficacy of regular vitamin
797 C (ascorbic acid) supplementation on upper-RTI incidence depends on individual physical
798 stress levels and associated immune perturbations. Broadly speaking, the data show no
799 benefit of chronic supplementation. A meta-analysis of 24 trials (>10,000 participants)
800 showed no effect of moderate- or high-dose vitamin C on the incidence of upper-RTI
801 (Hemilä and Chalker 2013). Accordingly, chronic vitamin C supplementation is not
802 justified in normal (vitamin C-replete) populations (Hemilä and Chalker 2013; Gómez et
803 al. 2018). The short-term, therapeutic effects of vitamin C are less conclusive (Hemilä and
804 Chalker 2013), but several reviews report that supplementation shortened the duration of
805 upper-RTI symptoms by ~8-18% (Hemilä and Chalker 2013; Abioye et al. 2021). It may
806 therefore be practical to initiate short-term vitamin C supplementation within 24 h of
807 symptom onset.

808 There is also evidence that acute supplementation may benefit individuals
809 undergoing periods of extreme physical stress. An analysis of five trials comprising
810 marathon runners, skiers, and soldiers, found that vitamin C supplementation reduced
811 symptoms of the common cold by ~50% following hard exercise (Hemilä and Chalker
812 2013). Further to moderating viral-mediated respiratory symptoms, the prophylactic
813 effects of vitamin C supplementation in some athletes may result from an attenuation of
814 EIB and associated symptoms (Tecklenburg et al. 2007; Hemilä 2013). Thus, when the
815 risk of infection in athletes is elevated due to a high training/competitive load (Ruuskanen
816 et al. 2022) or extensive travel (Walsh 2019), vitamin C supplementation (0.25-1.0 g·d⁻¹)
817 may reduce the severity and/or duration of upper-RTIs (Walsh 2019; Cerullo et al. 2020).
818 An important caveat is that chronic, high-dose (~1 g·d⁻¹) vitamin C supplementation may
819 blunt certain training-induced skeletal muscle adaptations (Mason et al. 2020), and is
820 therefore discouraged.

821 Lastly, there is some evidence that vitamin C may help ameliorate asthma
822 symptoms (Allen et al. 2009; Berthon and Wood 2015). An analysis of three small trials
823 (*n*=40) in asthmatics found that vitamin C supplementation, in various dosing regimens
824 (1.5 g·d⁻¹ for two weeks; 2 g ingested 1 h before exercise; 0.5 g ingested 1.5 h before
825 exercise), attenuated the post-exercise fall in FEV₁ by 48% (Hemilä 2013).
826 Notwithstanding, there is insufficient evidence to make decisive recommendations

827 regarding vitamin C supplementation for asthma management, and more RCTs with
828 larger samples are needed.

829 *2.6.4 Literature on Omega-3 (n-3) poly-unsaturated fatty acids (PUFAs).*

830 The most abundant PUFA in the Western diet is linoleic acid which is converted to
831 arachidonic acid—a precursor for pro-inflammatory and bronchoconstrictive signaling. By
832 contrast, omega-3 (n-3) PUFAs, including eicosapentaenoic acid (EPA) and
833 docosahexaenoic acid (DHA), derived primarily from fatty fish, may have anti-
834 inflammatory effects. Specifically, EPA inhibits arachidonic acid, blunts pro-inflammatory
835 signaling, and acts as a precursor for pro-resolving mediators with anti-inflammatory
836 properties (Brannan et al. 2015). Similarly, DHA has been shown to modify gene
837 expression and signaling pathways related to inflammatory mediators (Calder 2010).
838 Dietary supplementation with EPA and DHA has therefore been explored as an adjunct
839 therapy in certain respiratory conditions (Thien et al. 2002; Yang et al. 2013; Stoodley et
840 al. 2019).

841 Studies show that supplementation with high dose n-3 PUFAs for several weeks
842 mitigates EIB (Mickleborough et al. 2003, 2006; Tecklenburg-Lund et al. 2010;
843 Mickleborough and Lindley 2014; Kumar et al. 2016). Yet, because high dose n-3 PUFA
844 is expensive and may cause gastrointestinal complaints, it is worth noting that both high
845 dose (6.2 g/d) and moderate dose (3.1 g/d) n-3 PUFA appear to exert similar effects on
846 provocation-induced decreases in FEV₁ (Williams et al. 2017).

847 In COPD, studies with n-3 PUFA supplementation show equivocal results. A meta-
848 analysis of eight RCTs found that supplementation increased body mass, increased low-
849 density lipoproteins, and reduced IL-6, but did not influence lung function or quality of life
850 (Yu et al. 2021). These results should be interpreted cautiously because, depending on
851 disease severity and other comorbidities, weight gain may be beneficial for some COPD
852 patients and harmful for others. Moreover, some RCTs provide limited data regarding
853 individual doses of EPA and DHA. For example, an observational cohort study of
854 >120,000 US women and men initially showed that greater consumption of fish (>4
855 servings per week) was associated with lower risk of newly diagnosed COPD. But
856 subsequent analysis showed that COPD risk was unrelated to total n-3 PUFA intake
857 (Varraso et al. 2015). To date, only one observational cohort study in moderate-to-severe

858 COPD has shown that high dietary n-3 PUFA reduces risk of severe exacerbations,
859 decreases the number of respiratory symptoms, improves health-related quality of life,
860 and reduces overall morbidity (Lemoine et al. 2020). The same study showed the
861 opposite effects of high dietary n-6 PUFA (linoleic acid) (Lemoine et al. 2020). These data
862 speak to the importance of distinguishing n-3 from n-6 PUFA in supplementation
863 interventions, and the importance of the dietary n-3/n-6 PUFA ratio in respiratory health.
864 More well-controlled RCTs on n-3 PUFA supplementation in current and former smokers
865 with COPD are warranted.

866 *2.6.5 Literature on Probiotics, Prebiotics, and Synbiotics.*

867 The microbial profile and gut microbiome have a substantial influence on health and
868 disease (Clemente et al. 2012) and systemic immune function (Roberfroid et al. 2010).
869 Immune function is particularly important for respiratory health, and the “gut-lung axis”
870 represents a promising therapeutic target for the non-pharmacological management of
871 respiratory health and diseases (Marsland et al. 2015). Beneficial changes in the gut
872 microbiota can be achieved through dietary supplementation with probiotics (live
873 microorganisms that confer a health benefit on the host when administered in adequate
874 amounts) (Hill et al. 2014), prebiotics (substrates that are selectively utilized by host
875 microorganisms, conferring a health benefit) (Gibson et al. 2017), and/or synbiotics (a
876 combination of pro- and prebiotics).

877 In terms of the gut microbiota and its effects on respiratory health in subjects
878 without respiratory disease, the largest body of evidence relates to upper-RTIs, and the
879 data are largely favorable. For example, a 2015 Cochrane review of 10 trials found that
880 probiotics reduced the incidence of upper-RTI relative to placebo (Hao et al. 2015). Other
881 meta-analyses show similar findings in healthy infants, children, and adults after
882 supplementation with probiotics (six studies, $n = 1682$) (Rashidi et al. 2021) and synbiotics
883 (four RCTs, $n = 883$) (Chan et al. 2020). Probiotics may also decrease upper-RTI risk in
884 active individuals and athletes (Cox et al. 2010; West et al. 2011, 2014; Haywood et al.
885 2014; Strasser et al. 2016).

886 There is also preliminary data indicating that the gut-lung axis may be a suitable
887 target for managing asthma and related conditions. Prebiotics, probiotics, and synbiotics
888 each reduced airway inflammation and disease severity in rodent models of allergic

889 asthma (Sagar et al. 2014; Verheijden et al. 2015, 2016). Furthermore, a small-scale,
890 double-blind, placebo-controlled RCT showed potential benefits of prebiotics in adults
891 with EIB (Williams et al. 2016). Specifically, prebiotics reduced serum markers of airway
892 inflammation at baseline and completely abolished the 29% provocation-induced
893 increase in TNF- α (a pro-inflammatory cytokine). Lastly, eight weeks supplementation
894 with probiotics decreased asthma exacerbations in children when compared to placebo
895 (Drago et al. 2022). Although more RCTs in humans are warranted, the pre-clinical rodent
896 data and preliminary human *in-vivo* studies show potential benefits of pre- and/or
897 probiotics as a potential adjunct therapy to support respiratory health.

898 **2.6.6 Evidence Summary and Recommendations.** Primary outcomes from the
899 literature on nutritional interventions are summarized in **Figure 5**. The effects of chronic
900 vitamin D₃ supplementation on the prevalence/severity of upper-RTI are inconsistent.
901 When supplemented prophylactically, there is no evidence of benefits in asthma
902 management. In asthmatics and COPD patients with pre-existing deficiency, vitamin D₃
903 supplementation may confer therapeutic benefits. Long-term, daily supplementation of
904 vitamin C (ascorbic acid) provides little-to-no benefit in those who are vitamin C-replete
905 but may reduce the severity and/or duration of the common cold and symptoms of general
906 RTI when supplemented acutely at symptom onset (0.25-1.0 g·d⁻¹), especially in
907 individuals undergoing periods of extreme physical stress. Nevertheless, there is
908 insufficient evidence to support vitamin C supplementation for asthma management.
909 Several weeks of n-3 PUFAs reduce the severity of EIB but similar data in COPD are
910 equivocal, with only one observational cohort study showing reduced risk of exacerbation
911 and benefits to respiratory symptoms and overall morbidity. Daily probiotics and/or
912 prebiotics reduce the incidence of upper-RTI better than placebo in adults, children, active
913 individuals, and athletes. Prebiotics, probiotics, and synbiotics may also reduce airway
914 inflammation and disease severity in rodent models of allergic asthma, with preliminary
915 evidence showing benefits in adults with EIB.

916

917 **2.7 Inhaled L-menthol**

918 **2.7.1 Premise and plausibility.** L-menthol is a cyclic alcohol derived from the oils
919 of various species of *Mentha* (mints) that have been used as medicinal plants for

920 millennia. There is evidence that inhaled or ingested L-menthol triggers a cooling
921 sensation by stimulating sensory nerve endings in the nasal vestibule and mucosa that
922 convey nasal sensation (Aldren and Tolley 1993; Eccles 2003). Because L-menthol has
923 a significant effect on the sensation of nasal airflow, menthol vendors claim that the oil
924 can decongest the upper airways (e.g., during colds and allergies), enhance nasal flow,
925 and improve airway patency. Hence, L-menthol is widely available in lozenges, nasal
926 sprays, vapor rubs, inhalers, cough syrups, mouthwashes, as a scent in aromatherapy
927 oils, and as a flavoring in cigarettes and e-cigarettes. However, the plausibility of L-
928 menthol to improve respiratory function is low because it does not possess the amine
929 group that would be expected of a substance with vasodilator or bronchodilator
930 properties, nor does it have a chemical structure similar to nasal decongestants (Eccles
931 et al. 1988; Eccles 1994). Accordingly, any benefit of L-menthol is likely to be indirect—
932 mediated by cooling sensations that stimulate the nasal trigeminal nerve thereby creating
933 the cognitive illusion of improved inspiratory flow (Kanezaki et al. 2021).

934 *2.7.2 Literature.* Articles were excluded if L-menthol was not inhaled, dissolved and
935 nebulized, ingested orally on a lozenge, rinsed/swilled in the mouth, if the effects of L-
936 menthol could not be distinguished from other substances that were co-administered, or
937 if the article did not assess respiratory function. It is well-established that healthy adults
938 (free from respiratory disorders and the common cold) experience increased sensations
939 of nasal airflow and/or nasal patency after inhaling L-menthol (Eccles et al. 1988; Pereira
940 et al. 2013). Two randomized, placebo-controlled trials showed that inhaling L-menthol
941 reduced sensations of respiratory discomfort during flow-resistive and elastic loading at
942 rest (Nishino et al. 1997) and inspiratory resistive loading during exercise (Kanezaki and
943 Ebihara 2017). Studies in individuals with the common cold also found that a menthol-
944 containing lozenge evoked marked improvements in sensations of nasal airflow and
945 decongestion (Eccles et al. 1990; EccleS et al. 1990). Yet, subjective changes in
946 respiratory perceptions are not reflected in objective changes in breathing patterns (i.e.,
947 respiratory frequency, tidal volume, or inspiratory flow), minute ventilation, or spirometric
948 indices of lung function (Nishino et al. 1997; Kanezaki and Ebihara 2017). Case in point,
949 Köteles *et al.* (2018) showed that nebulized menthol-containing peppermint, rosemary, or
950 eucalyptus oil, inhaled over 15 minutes, had no effect on FVC, FEV₁/FVC, or peak

951 expiratory flow (PEF), despite improving the perceptions of spirometric outcomes.
952 Similarly, the only study to assess upper-airway resistance using rhinometry confirmed
953 no effect of menthol on nasal/upper-airway resistance, respiratory frequency, or minute
954 ventilation in healthy adults at rest (Pereira et al. 2013).

955 In obstructive respiratory disorders, the data tend to follow a similar pattern. During
956 inspiratory resistive loading in patients with mild-to-severe COPD, L-menthol significantly
957 improved subjective measures (i.e., physical and mental “breathing effort”, air hunger,
958 breathing discomfort, and anxiety and fear) relative to a non-L-menthol control, but did
959 not influence objective measures (i.e., breathing pattern, respiratory duty cycle, and
960 inspiratory muscle activity) (Kanezaki et al. 2020). Others have observed no difference
961 between nebulized menthol and placebo on FVC or FEV₁ in mild asthmatics (Tamaoki et
962 al. 1995). A randomized, double-blind trial in patients with chronic cough found that, in
963 response to a capsaicin provocation test, inhalation of 1 mL nebulized L-menthol (0.5%
964 and 1% concentration) improved peak inspiratory flow relative to placebo, whereas only
965 high-dose L-menthol (1%) attenuated the reduction in forced inspiratory flow at 50% of
966 vital capacity (FIF₅₀) and increased the cough threshold (Millqvist et al. 2013). A single-
967 blind (non-placebo-controlled) study of L-menthol-containing “aromatics” observed
968 improved mucous clearance in patients with chronic bronchitis when compared to
969 petroleum jelly, but no effect on lung function (Hasani et al. 2003). Lastly, although studies
970 have generally failed to observe any direct effect of L-menthol on physiological variables
971 during exercise, there is a possible indirect effect of L-menthol on exercise performance
972 in the heat owing to changes in the sensation of oropharyngeal temperature versus
973 placebo (Mündel and Jones 2010).

974 *2.7.3 Evidence Summary and Recommendations.* Primary outcomes from the
975 literature on inhaled L-menthol are summarized in **Figure 6**. By stimulating sensory nerve
976 endings in the nasal vestibule, inhaled L-menthol can augment sensations of nasal
977 airflow, improve respiratory perceptions in both healthy subjects and patients, and
978 potentially relieve dyspnea in COPD. Improved respiratory perceptions may translate to
979 improved exercise performance in the heat. There is some evidence that high-
980 concentration inhaled L-menthol may increase the cough threshold in patients with
981 chronic cough. Nevertheless, L-menthol does not have vasodilator or bronchodilator

982 properties, and there is little-to-no convincing evidence that L-menthol has direct
983 functional benefits on spirometry-related variables in any population.

984

985 **Conclusions**

986 The health and wellness industry is characterized by, and in many cases depends
987 on, lax consumer regulations regarding the products and services sold therein. As a
988 result, interventions are often sold on insufficient evidence, baseless claims, and
989 pseudoscience (Tiller et al. 2022). Not only is there a growing disparity between the
990 substance of commercial claims and the supporting scientific evidence, thereby violating
991 Laplace’s principle that “Extraordinary claims require extraordinary evidence”, but the
992 legitimate (plausible) and illegitimate (implausible) claims for these interventions are often
993 conflated, obscuring the translation of science to practice. This is a particular problem in
994 the field on respiratory physiology and medicine.

995 This review is intended as an evidence-based guide to help health and exercise
996 professionals distinguish science from pseudoscience in commercial respiratory
997 interventions and make informed decisions that optimize patient/client outcomes. This
998 review is intended as an evidence-based guide to help health and exercise professionals
999 distinguish science from pseudoscience in commercial respiratory interventions and
1000 make informed decisions that optimize patient/client outcomes. In summarizing the
1001 recommendations, there are several caveats that should be noted. First, the
1002 products/strategies selected for inclusion were commercial interventions (i.e., not
1003 controlled drugs or products regulated by the FDA as “medical devices”). The list was
1004 delimited to those interventions most prevalent in the health and wellness industry that
1005 were coupled to the most conspicuous claims, and there may be prominent, mainstream
1006 interventions that were not included.

1007 A second caveat is that the recommendations herein are based on data from
1008 controlled laboratory-based studies. The statistical analyses typically used allowed
1009 researchers to reject, or fail to reject, the null hypotheses, and subsequently discuss the
1010 existence of effects or lack thereof. Yet, such an approach is dichotomous by design,
1011 providing little room for nuanced interpretation of differences, potentially overlooking
1012 practical or clinical implications. For example, some studies in exercise rehabilitation have

1013 been shown to yield non-significant between-group differences despite moderate-to-large
1014 effects that would be deemed meaningful in practice (Zemková 2014). Interventions with
1015 moderate-to-large effects, despite lack of statistical significance, may be especially
1016 important for high-performance athletes for whom the margins of success are extremely
1017 small. The opposite may also be true (i.e., statistical tests may yield highly significant
1018 outcomes with trivial effects). To improve external validity in exercise-based studies,
1019 researchers have been encouraged to perform robust statistical analyses (e.g., by using
1020 appropriate sample sizes, correcting for familywise error rate, etc.) but report them
1021 alongside confidence intervals and/or effect sizes as a measure of “practical significance”
1022 (Knudson 2009). This might aid in the interpretation of both “statistically significant” and
1023 “practically meaningful” outcomes.

1024 In this comprehensive review of literature and expert consensus, overall it was
1025 determined that: (1) there is good quality data supporting subjective/perceptual (but not
1026 objective) benefits of both nasal dilators and L-menthol; (2) there is some evidence that
1027 nasally-derived nitric oxide may benefit critically ill patients but not healthy subjects; (3)
1028 there is good evidence that systematized breathing interventions (particularly pursed-lips
1029 breathing) can improve exercise performance, respiratory symptoms, and quality of life in
1030 COPD and asthma; (4) there is good evidence that respiratory muscle training can
1031 improve exercise performance in healthy subjects and respiratory symptoms in some
1032 patient populations (e.g., COPD), with benefits for patients with COPD who have
1033 respiratory muscle weakness or pre-existing comorbidities precluding them from whole-
1034 body exercise training; (5) there is evidence that nutritional interventions including vitamin
1035 D and vitamin C may benefit respiratory health in individuals with pre-existing nutrient
1036 deficiency and during times of compromised immune function second to increased
1037 physical stress, and interesting but inconsistent evidence of benefits of polyunsaturated
1038 fatty acids and pre/probiotics/synbiotics; and (6) no evidence that canned oxygen is
1039 beneficial for any clinical outcome.

1040 For the interventions aforementioned, we advocate for greater vigilance in determining
1041 prior plausibility and evidence for efficacy. We also hope to inspire similar expert reviews
1042 that scrutinize interventions stemming from other facets of the commercial health and
1043 wellness industry.

1044

1045 **Declarations**

1046 *Funding.* No funding was received to develop this manuscript. Nicholas B. Tiller is
1047 funded by a postdoctoral fellowship from the Tobacco-Related Disease Research
1048 Program (TRDRP; award no. T31FT1692). Camilla R. Illidi is funded by an Accelerate
1049 postdoctoral fellowship from the Mathematics of Information Technology and Complex
1050 System (MITACS award no. IT28775).

1051 *Conflicts of interest.* All authors declare that they have no conflicts of interest
1052 relevant to the content of this review.

1053 *Authors' contributions.* CRI and NBT conceived the manuscript. All authors
1054 drafted, edited, and approved the final version.

1055

1056 **Footnote, page 17**

1057 ¹Applied external resistors are intentionally designed to elicit high resistive loads during
1058 exercise; thus, they impose considerably greater loads than low-resistance face
1059 coverings (e.g., cloth and surgical masks) that might be used for personal protection
1060 from airborne pathogens. Indeed, the negative physiological effects of protective face
1061 masks have been shown to be negligible when used during physical activity in healthy
1062 individuals (Hopkins et al. 2021).

1063

1064 **REFERENCES**

1065

1066 Abioye AI, Bromage S, Fawzi W (2021) Effect of micronutrient supplements on influenza and
1067 other respiratory tract infections among adults: a systematic review and meta-analysis.
1068 *BMJ Global Health* 6:e003176. <https://doi.org/10.1136/bmjgh-2020-003176>

1069 Adams CM, Peiffer JJ (2017) Neither internal nor external nasal dilation improves cycling 20-km
1070 time trial performance. *Journal of Science and Medicine in Sport* 20:415–9.
1071 <https://doi.org/10.1016/j.jsams.2016.08.018>

1072 Ahmed S, Martin A, Anatole D, Smith BK (2019) Inspiratory muscle training in patients with
1073 prolonged mechanical ventilation: Narrative review. *Cardiopulmonary Physical Therapy*
1074 *Journal* 30:44–50. <https://doi.org/10.1097/CPT.0000000000000092>

1075 Aldren C, Tolley NS (1993) Further studies on nasal sensation of airflow. *Rhinology* 29:49–55

1076 Allen S, Britton JR, Leonardi-Bee JA (2009) Association between antioxidant vitamins and
1077 asthma outcome measures: systematic review and meta-analysis. *Thorax* 64:610–619.
1078 <https://doi.org/10.1136/THX.2008.101469>

1079 Amann M, Regan MS, Kobitany M, et al (2010) Impact of pulmonary system limitations on
1080 locomotor muscle fatigue in patients with COPD. *American Journal of Physiology:*
1081 *Regulatory, Integrative and Comparative Physiology* 299:R314-324.
1082 <https://doi.org/10.1152/ajpregu.00183.2010.-We>

1083 Amaro ACS, Duarte FHG, Jallad RS, et al (2012) The use of nasal dilator strips as a placebo for
1084 trials evaluating continuous positive airway pressure. *Clinics* 67:469–474.
1085 [https://doi.org/10.6061/clinics/2012\(05\)11](https://doi.org/10.6061/clinics/2012(05)11)

1086 Anderson SD, Kippelen P (2012) Assessment and prevention of exercise-induced
1087 bronchoconstriction. *British Journal of Sports Medicine* 46:391–396.
1088 <https://doi.org/10.1136/bjsports-2011-090810>

1089 Andújar-Espinosa R, Salinero-González L, Illán-Gómez F, et al (2021) Effect of vitamin D
1090 supplementation on asthma control in patients with vitamin D deficiency: the ACVID
1091 randomised clinical trial. *Thorax* 76:126–133. <https://doi.org/10.1136/THORAXJNL-2019-213936>

1093 Arnedillo A, Gonzalez-Montesinos JL, Fernandez-Santos JR, et al (2020) Effects of a
1094 rehabilitation programme with a nasal inspiratory restriction device on exercise capacity
1095 and quality of life in COPD. *International Journal of Environmental Research and Public*
1096 *Health* 17:3669. <https://doi.org/10.3390/IJERPH17103669>

1097 Azambuja ADCM, De Oliveira LZ, Sbruzzi G (2020) Inspiratory muscle training in patients with
1098 heart failure: What is new? Systematic review and meta-analysis. *Physical Therapy*
1099 100:2099–2109. <https://doi.org/10.1093/PTJ/PZAA171>

- 1100 Bachasson D, Wuyam B, Pepin JL, et al (2013) Quadriceps and respiratory muscle fatigue
 1101 following high-intensity cycling in COPD patients. *PloS one* 8:e83432.
 1102 <https://doi.org/10.1371/journal.pone.0083432>
- 1103 Bahammam AA, Tate R, Manfreda J, Kryger MH (1999) Upper airway resistance syndrome:
 1104 effect of nasal dilation, sleep stage, and sleep position. *Sleep* 22:592–598
- 1105 Banzett RB, Lansing RW, Binks AP (2021) Air hunger: A primal sensation and a primary
 1106 element of dyspnea. *Comprehensive Physiology* 11:1449–1483.
 1107 <https://doi.org/10.1002/CPHY.C200001>
- 1108 Barnes CS, Alexis NE, Bernstein JA, et al (2013) Climate change and our environment: The
 1109 effect of respiratory and allergic disease. *Journal of Allergy and Clinical Immunology in*
 1110 *Practice* 1:137–141. <https://doi.org/10.1016/j.jaip.2012.07.002>. Climate
- 1111 Beaumont M, Forget P, Couturaud F, Reyckler G (2018a) Effects of inspiratory muscle training
 1112 in COPD patients: A systematic review and meta-analysis. *The Clinical Respiratory*
 1113 *Journal* 12:2178–2188. <https://doi.org/10.1111/CRJ.12905>
- 1114 Beaumont M, Mialon P, Le Ber C, et al (2018b) Effects of inspiratory muscle training on
 1115 dyspnoea in severe COPD patients during pulmonary rehabilitation: controlled
 1116 randomised trial. *The European Respiratory Journal* 51:1701107.
 1117 <https://doi.org/10.1183/13993003.01107-2017>
- 1118 Becquemin MH, Swift DL, Bouchikhi A, et al (1991) Particle deposition and resistance in the
 1119 noses of adults and children. *European Respiratory Journal* 4:694–702
- 1120 Bener A, Ehlal MS, Bener HZ, Hamid Q (2014) The impact of Vitamin D deficiency on
 1121 asthma, allergic rhinitis and wheezing in children: An emerging public health problem.
 1122 *Journal of Family and Community Medicine* 21:154–161. [https://doi.org/10.4103/2230-](https://doi.org/10.4103/2230-8229.142967)
 1123 [8229.142967](https://doi.org/10.4103/2230-8229.142967)
- 1124 Bennett WD, Zeman KL, Jarabek AM (2003) Nasal contribution to breathing with exercise:
 1125 Effect of race and gender. *Journal of Applied Physiology* 95:497–503.
 1126 <https://doi.org/10.1152/jappphysiol.00718.2002>
- 1127 Berthon BS, Wood LG (2015) Nutrition and respiratory health – Feature review. *Nutrients*
 1128 7:1618–1643. <https://doi.org/10.3390/nu7031618>
- 1129 Bhatt SP, Luqman-Arafath TK, Gupta AK, et al (2013) Volitional pursed lips breathing in patients
 1130 with stable chronic obstructive pulmonary disease improves exercise capacity. *Chronic*
 1131 *Respiratory Disease* 10:5–10. <https://doi.org/10.1177/1479972312464244>
- 1132 Bishop CA, Johnson SM, Wall MB, et al (2016) Magnetic resonance imaging reveals the
 1133 complementary effects of decongestant and Breathe Right Nasal Strips on internal nasal
 1134 anatomy. *Laryngoscope* 126:2205–2211. <https://doi.org/10.1002/lary.25906>
- 1135 Boggs GW, Ward JR, Stavrianeas S (2008) The external nasal dilator: style over function?
 1136 *Journal of Strength and Conditioning Research* 22:269–75.
 1137 <https://doi.org/10.1519/JSC.0b013e31815f903e>

- 1138 Brannan JD, Bood J, Alkhabaz A, et al (2015) The effect of omega-3 fatty acids on bronchial
 1139 hyperresponsiveness, sputum eosinophilia, and mast cell mediators in asthma. *Chest*
 1140 147:397–405. <https://doi.org/10.1378/CHEST.14-1214>
- 1141 Brawley A, Silverman B, Kearney S, et al (2004) Allergic rhinitis in children with attention-
 1142 deficit/hyperactivity disorder. *Annals of Allergy, Asthma & Immunology* 92:663–667.
 1143 [https://doi.org/10.1016/S1081-1206\(10\)61434-2](https://doi.org/10.1016/S1081-1206(10)61434-2)
- 1144 Breslin EH (1992) The pattern of respiratory muscle recruitment during pursed-lip breathing.
 1145 *Chest* 101:75–78. <https://doi.org/10.1378/chest.101.1.75>
- 1146 Bruton A, Lewith GT (2005) The Buteyko breathing technique for asthma: a review.
 1147 *Complementary Therapies in Medicine* 13:41–46.
 1148 <https://doi.org/10.1016/J.CTIM.2005.01.003>
- 1149 Burgess J, Ekanayake B, Lowe A, et al (2011) Systematic review of the effectiveness of
 1150 breathing retraining in asthma management. *Expert Review of Respiratory Medicine*
 1151 5:789–807. <https://doi.org/10.1586/ERS.11.69>
- 1152 Cabral LF, D'Elia TDC, Marins DDS, et al (2015) Pursed lip breathing improves exercise
 1153 tolerance in COPD: a randomized crossover study. *European Journal of Physical and*
 1154 *Rehabilitation Medicine* 51:79–88
- 1155 Cahalin LP, Braga M, Matsuo Y, Hernandez ED (2002) Efficacy of diaphragmatic breathing in
 1156 persons with chronic obstructive pulmonary disease: A review of the literature. *Journal of*
 1157 *Cardiopulmonary Rehabilitation* 22:7–21. [https://doi.org/10.1097/00008483-200201000-](https://doi.org/10.1097/00008483-200201000-00002)
 1158 [00002](https://doi.org/10.1097/00008483-200201000-00002)
- 1159 Calder PC (2010) Omega-3 fatty acids and inflammatory processes. *Nutrients* 2:355–374.
 1160 <https://doi.org/10.3390/NU2030355>
- 1161 Camacho M, Malu OO, Kram YA, et al (2016) Nasal dilators (Breathe Right strips and
 1162 NoZovent) for snoring and OSA: A systematic review and meta-analysis. *Pulmonary*
 1163 *Medicine* 2016:4841310. <https://doi.org/10.1155/2016/4841310>
- 1164 Carswell AT, Oliver SJ, Wentz LM, et al (2018) Influence of vitamin D supplementation by
 1165 sunlight or oral D3 on exercise performance. *Medicine and Science in Sports and*
 1166 *Exercise* 50:2555–2564. <https://doi.org/10.1249/MSS.0000000000001721>
- 1167 Casaburi R (2008) A brief history of pulmonary rehabilitation. *Respiratory Care* 53:1185–1189
- 1168 Cashman KD, Dowling KG, Skrabáková Z, et al (2016) Vitamin D deficiency in Europe:
 1169 pandemic? *American Journal of Clinical Nutrition* 103:1033–1077.
 1170 <https://doi.org/10.3945/ajcn.115.120873>
- 1171 Cena H, Calder PC (2020) Defining a healthy diet: Evidence for the role of contemporary dietary
 1172 patterns in health and disease. *Nutrients* 12:334. <https://doi.org/10.3390/nu12020334>
- 1173 Cerullo G, Negro M, Parimbelli M, et al (2020) The long history of vitamin C: From prevention of
 1174 the common cold to potential aid in the treatment of COVID-19. *Frontiers in Immunology*
 1175 11:574029. <https://doi.org/10.3389/FIMMU.2020.574029>

- 1176 Chambault J, Grand G, Kayser B (2021) Sex-specific effects of respiratory muscle endurance
1177 training on cycling time trial performance in normoxia and hypoxia. *Frontiers in*
1178 *Physiology* 12:1–8. <https://doi.org/10.3389/fphys.2021.700620>
- 1179 Chan CKY, Tao J, Chan OS, et al (2020) Preventing respiratory tract infections by synbiotic
1180 interventions: A systematic review and meta-analysis of randomized controlled trials.
1181 *Advances in Nutrition* 11:979–988. <https://doi.org/10.1093/ADVANCES/NMAA003>
- 1182 Charususin N, Gosselink R, Decramer M, et al (2018a) Randomised controlled trial of adjunctive
1183 inspiratory muscle training for patients with COPD. *Thorax* 73:942–950.
1184 <https://doi.org/10.1136/THORAXJNL-2017-211417>
- 1185 Charususin N, Gosselink R, Decramer M, et al (2018b) Randomised controlled trial of adjunctive
1186 inspiratory muscle training for patients with COPD. *Thorax* 73:942–950.
1187 <https://doi.org/10.1136/THORAXJNL-2017-211417>
- 1188 Chen FY, Xiao M, Ling B, et al (2019) Vitamin D does not improve lung function decline in
1189 COPD: a meta-analysis. *European Review for Medical and Pharmacological Sciences*
1190 23:8637–8644. https://doi.org/10.26355/EURREV_201910_19181
- 1191 Chen Z, Peng C, Mei J, et al (2021) Vitamin D can safely reduce asthma exacerbations among
1192 corticosteroid-using children and adults with asthma: a systematic review and meta-
1193 analysis of randomized controlled trials. *Nutrition Research* 92:49–61.
1194 <https://doi.org/10.1016/J.NUTRES.2021.05.010>
- 1195 Cheng HM, Kim S, Park GH, et al (2014) Low vitamin D levels are associated with atopic
1196 dermatitis, but not allergic rhinitis, asthma, or IgE sensitization, in the adult Korean
1197 population. *The Journal of allergy and clinical immunology* 133:1048–1055.
1198 <https://doi.org/10.1016/J.JACI.2013.10.055>
- 1199 Cherrie MPC, Sarran C, Osborne NJ (2017) Supplementary materials: Association between
1200 serum 25-hydroxyvitamin D levels and the prevalence of adult-onset asthma.
1201 *International Journal of Environmental Research and Public Health* 15:1103.
1202 <https://doi.org/10.3390/ijerph15061103>
- 1203 Cho H, Myung SK, Cho HE (2022) Efficacy of vitamin D supplements in treatment of acute
1204 respiratory infection: A meta-analysis for randomized controlled trials. *Nutrients* 14:1144.
1205 <https://doi.org/10.3390/nu14061144>
- 1206 Clemente JC, Ursell LK, Parfrey LW, Knight R (2012) The impact of the gut microbiota on
1207 human health: an integrative view. *Cell* 148:1258–1270.
1208 <https://doi.org/10.1016/J.CELL.2012.01.035>
- 1209 Confino-Cohen R, Brufman I, Goldberg A, Feldman BS (2014) Vitamin D, asthma prevalence
1210 and asthma exacerbations: a large adult population-based study. *Allergy* 69:1673–1680.
1211 <https://doi.org/10.1111/ALL.12508>
- 1212 Cooper S, Osborne J, Harrison T, Tattersfield A (2009) Effect of mouth taping at night on asthma
1213 control – a randomised single-blind crossover study. *Respiratory Medicine* 103:813–819.
1214 <https://doi.org/10.1016/J.RMED.2009.02.003>

- 1215 Courtney R, Cohen M (2008) Investigating the claims of Konstantin Buteyko, M.D., Ph.D.: the
 1216 relationship of breath holding time to end tidal CO₂ and other proposed measures of
 1217 dysfunctional breathing. *Journal of Alternative and Complementary Medicine* 14:115–
 1218 123. <https://doi.org/10.1089/ACM.2007.7204>
- 1219 Cox AJ, Pyne DB, Saunders PU, Fricker PA (2010) Oral administration of the probiotic
 1220 *Lactobacillus fermentum* VRI-003 and mucosal immunity in endurance athletes. *British*
 1221 *journal of sports medicine* 44:222–226. <https://doi.org/10.1136/BJSM.2007.044628>
- 1222 Craighead DH, Tavoian D, Freeberg KA, et al (2022) A multi-trial, retrospective analysis of the
 1223 antihypertensive effects of high-resistance, low-volume inspiratory muscle strength
 1224 training. *Journal of applied physiology* (Bethesda, Md : 1985) 133:.
 1225 <https://doi.org/10.1152/JAPPLPHYSIOL.00425.2022>
- 1226 Crespo AS, Hallberg J, Lundberg JO, et al (2010) Nasal nitric oxide and regulation of human
 1227 pulmonary blood flow in the upright position. *Journal of Applied Physiology* 108:181–
 1228 188. <https://doi.org/10.1152/jappphysiol.00285.2009>
- 1229 Critchley HD, Nicotra A, Chiesa PA, et al (2015) Slow breathing and hypoxic challenge:
 1230 Cardiorespiratory consequences and their central neural substrates. *PLoS ONE*
 1231 10:e0127082. <https://doi.org/10.1371/journal.pone.0127082>
- 1232 Dallam GM, McClaran SR, Cox DG, Foust CP (2018) Effect of nasal versus oral breathing on
 1233 Vo₂max and physiological economy in recreational runners following an extended period
 1234 spent using nasally restricted breathing. *International Journal of Kinesiology and Sports*
 1235 *Science* 6:22–29. <https://doi.org/10.7575/aiac.ijkss.v.6n.2p.22>
- 1236 De Troyer A, Wilson TA (2009) Effect of acute inflation on the mechanics of the inspiratory
 1237 muscles. *Journal of Applied Physiology* 107:315–323.
 1238 <https://doi.org/10.1152/JAPPLPHYSIOL.91472.2008>
- 1239 Dempsey JA, Gerche A La, Hull JH (2020) Is the healthy respiratory system built just right,
 1240 overbuilt, or underbuilt to meet the demands imposed by exercise? *Journal of Applied*
 1241 *Physiology* 129:1235–1256. <https://doi.org/10.1152/JAPPLPHYSIOL.00444.2020>
- 1242 Di Somma EM, West SN, Wheatley JR, Amis TC (1999) Nasal dilator strips increase maximum
 1243 inspiratory flow via nasal wall stabilization. *Laryngoscope* 109:780–784.
 1244 <https://doi.org/10.1097/00005537-199905000-00018>
- 1245 Dinardi RR, de Andrade CR, da Cunha Ibiapina C (2017) Effect of the external nasal dilator on
 1246 adolescent athletes with and without allergic rhinitis. *International Journal of Pediatric*
 1247 *Otorhinolaryngology* 97:127–134. <https://doi.org/10.1016/j.ijporl.2017.04.008>
- 1248 Dinardi RR, Ribeiro De Andrade C, Da Cunha Ibiapina C (2014) External nasal dilators:
 1249 Definition, background, and current uses. *International Journal of General Medicine*
 1250 7:491–504. <https://doi.org/10.2147/IJGM.S67543>
- 1251 Dinardi RR, Ribeiro De Andrade C, Da Cunha Ibiapina C (2013) Evaluation of the effectiveness
 1252 of the external nasal dilator strip in adolescent athletes: A randomized trial. *International*
 1253 *Journal of Pediatric Otorhinolaryngology* 77:1500–1505.
 1254 <https://doi.org/10.1016/j.ijporl.2013.06.018>

- 1255 Dinardi RR, Santos Ferreira CH, Santos Silveira G, et al (2021) Does the external nasal dilator
 1256 strip help in sports activity? A systematic review and meta-analysis. *Eur Arch*
 1257 *Otorhinolaryngol* 278:1307–1320. <https://doi.org/10.1007/s00405-020-06202-5>
- 1258 Dominguez LJ, Di Bella G, Veronese N, Barbagallo M (2021) Impact of Mediterranean diet on
 1259 chronic non-communicable diseases and longevity. *Nutrients* 13:2028.
 1260 <https://doi.org/10.3390/nu13062028>
- 1261 Drago L, Cioffi L, Giuliano M, et al (2022) A post hoc analysis on the effects of a probiotic
 1262 mixture on asthma exacerbation frequency in schoolchildren. *ERJ Open Research*
 1263 8:00020–02022. <https://doi.org/10.1183/23120541.00020-2022>
- 1264 Dsouza FV, Amaravadi SK, Samuel SR, et al (2021) Effectiveness of expiratory muscle
 1265 training on respiratory muscle strength in patients undergoing cardiac surgeries: A
 1266 systematic review with meta-analysis. *Annals of Rehabilitation Medicine* 45:264–273.
 1267 <https://doi.org/10.5535/ARM.21027>
- 1268 Eccles R (1994) Menthol and related cooling compounds. *Journal of Pharmacy and*
 1269 *Pharmacology* 46:618–630. <https://doi.org/10.1111/J.2042-7158.1994.TB03871.X>
- 1270 Eccles R (2003) Menthol: Effects on nasal sensation of airflow and the drive to breathe. *Current*
 1271 *Allergy and Asthma Reports* 3:210–214. <https://doi.org/10.1007/S11882-003-0041-6>
- 1272 Eccles R, Griffiths DH, Newton CG, Tolley NS (1988) The effects of menthol isomers on nasal
 1273 sensation of airflow. *Clinical Otolaryngology & Allied Sciences* 13:25–29.
 1274 <https://doi.org/10.1111/j.1365-2273.1988.tb00277.x>
- 1275 Eccles R, Jawad MS, Morris S (1990) The effects of oral administration of (–)-menthol on nasal
 1276 resistance to airflow and nasal sensation of airflow in subjects suffering from nasal
 1277 congestion associated with the common cold. *Journal of Pharmacy and Pharmacology*
 1278 42:652–654. <https://doi.org/10.1111/j.2042-7158.1990.tb06625.x>
- 1279 Eccles R, Morris S, Jawad MS (1990) The effects of menthol on reaction time and nasal
 1280 sensation of airflow in subjects suffering from the common cold. *Clinical Otolaryngology*
 1281 *& Allied Sciences* 15:39–42. <https://doi.org/10.1111/j.1365-2273.1990.tb00430.x>
- 1282 Ehteshami-Afshar S, FitzGerald JM, Doyle-Waters MM, Sadatsafavi M (2016) The global
 1283 economic burden of asthma and chronic obstructive pulmonary disease. *International*
 1284 *Journal of Tuberculosis and Lung Disease* 20:11–23.
 1285 <https://doi.org/10.5588/ijtld.15.0472>
- 1286 Elizondo S, Ayala-Sanchez D, Choi W, et al (2019) Physiological effects of supplemental
 1287 concentrated oxygen in $\dot{V}O_2$ kinetics during steady-state exercise
- 1288 Fabero-Garrido R, del Corral T, Angulo-Díaz-Parreño S, et al (2022) Respiratory muscle training
 1289 improves exercise tolerance and respiratory muscle function/structure post-stroke at
 1290 short term: A systematic review and meta-analysis. *Annals of physical and rehabilitation*
 1291 *medicine* 65:. <https://doi.org/10.1016/J.REHAB.2021.101596>
- 1292 Faghy MA, Brown PI (2015) Training the inspiratory muscles improves running performance
 1293 when carrying a 25 kg thoracic load in a backpack.

- 1294 <http://dx.doi.org/101080/1746139120151071878> 16:585–594.
 1295 <https://doi.org/10.1080/17461391.2015.1071878>
- 1296 Faghy MA, Brown PI, Davis NM, et al (2021) A flow resistive inspiratory muscle training mask
 1297 worn during high-intensity interval training does not improve 5 km running time-trial
 1298 performance. *European journal of applied physiology* 121:183–191.
 1299 <https://doi.org/10.1007/S00421-020-04505-3>
- 1300 Farrokhyar F, Tabasinejad R, Dao D, et al (2014) Prevalence of vitamin D inadequacy in
 1301 athletes: A systematic-review and meta-analysis. *Sports Medicine* 45:365–378.
 1302 <https://doi.org/10.1007/S40279-014-0267-6>
- 1303 Ferraro F V, Gavin JP, Wainwright T, McConnell A (2019) The effects of 8 weeks of inspiratory
 1304 muscle training on the balance of healthy older adults: a randomized, double-blind,
 1305 placebo-controlled study. *Physiological Reports* 7:e14076.
 1306 <https://doi.org/10.14814/PHY2.14076>
- 1307 Ferraro F V, Gavin JP, Wainwright TW, McConnell AK (2020) Comparison of balance changes
 1308 after inspiratory muscle or Otago exercise training. *PLoS ONE* 15:1–16.
 1309 <https://doi.org/10.1371/journal.pone.0227379>
- 1310 Ferraro F V, Gavin JP, Wainwright TW, McConnell AK (2022) Association between inspiratory
 1311 muscle function and balance ability in older people: A pooled data analysis before and
 1312 after inspiratory muscle training. *Journal of Ageing and Physical Activity* 30:421–433.
 1313 <https://doi.org/10.1123/JAPA.2020-0507>
- 1314 Forno E, Bacharier LB, Phipatanakul W, et al (2020) Effect of vitamin D3 supplementation on
 1315 severe asthma exacerbations in children with asthma and low vitamin D levels: The
 1316 VDKA randomized clinical trial. *Journal of the American Medical Association* 324:752–
 1317 760. <https://doi.org/10.1001/JAMA.2020.12384>
- 1318 Foumani AA, Mehrdad M, Jafarinezhad A, et al (2019) Impact of vitamin D on spirometry
 1319 findings and quality of life in patients with chronic obstructive pulmonary disease: a
 1320 randomized, double-blinded, placebo-controlled clinical trial. *International Journal of*
 1321 *Chronic Obstructive Pulmonary Disease* 14:1495–1501.
 1322 <https://doi.org/10.2147/COPD.S207400>
- 1323 Garrod R, Dallimore K, Cook J, et al (2005) An evaluation of the acute impact of pursed lips
 1324 breathing on walking distance in nonspontaneous pursed lips breathing chronic
 1325 obstructive pulmonary disease patients. *Chronic Respiratory Disease* 2:67–72.
 1326 <https://doi.org/10.1191/1479972305cd068oa>
- 1327 Gelardi M, Porro G, Sterlicchio B, et al (2019) Internal and external nasal dilatator in patients
 1328 who snore: A comparison in clinical practice. *Acta Biomedica* 90:10–14.
 1329 <https://doi.org/10.23750/abm.v90i2-S.8096>
- 1330 Gerlach H, Rossaint R, Pappert D, Falke KJ (1993) Time-course and dose-response of nitric
 1331 oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with
 1332 adult respiratory distress syndrome. *European Journal of Clinical Investigation* 23:499–
 1333 502. <https://doi.org/10.1111/j.1365-2362.1993.tb00797.x>

- 1334 Gibson GR, Hutkins R, Sanders ME, et al (2017) Expert consensus document: The International
 1335 Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the
 1336 definition and scope of prebiotics. *Nature Reviews: Gastroenterology & Hepatology*
 1337 14:491–502. <https://doi.org/10.1038/NRGASTRO.2017.75>
- 1338 Ginde AA, Mansbach JM, Camargo CA (2009) Association between serum 25-hydroxyvitamin D
 1339 level and upper respiratory tract infection in the Third National Health and Nutrition
 1340 Examination Survey. *Archives of Internal Medicine* 169:384–390.
 1341 <https://doi.org/10.1001/archinternmed.2008.560>
- 1342 Global Initiative for Chronic Obstructive Lung Disease Inc (2022) Global Strategy for the
 1343 Diagnosis, management, and Prevention of Chronic Obstructive Pulmonary Disease
- 1344 Gómez E, Quidel S, Bravo-Soto G, Ortigoza Á (2018) Does vitamin C prevent the common
 1345 cold? *Medwave* 18:e7235. <https://doi.org/10.5867/MEDWAVE.2018.04.7236>
- 1346 Gonzalez-Montesinos JL, Fernandez-Santos JR, Vaz-Pardal C, et al (2021) Chronic effects of a
 1347 training program using a nasal inspiratory restriction device on elite cyclists. *International*
 1348 *Journal of Environmental Research and Public Health* 18:1–13.
 1349 <https://doi.org/10.3390/IJERPH18020777>
- 1350 Gosselink R, De Vos J, Van Den Heuvel SP, et al (2011) Impact of inspiratory muscle training in
 1351 patients with COPD: What is the evidence? *European Respiratory Journal* 37:416–425.
 1352 <https://doi.org/10.1183/09031936.00031810>
- 1353 Gosselink R, Wagenaar RC, Rijswijk H, et al (2012) Diaphragmatic breathing reduces efficiency
 1354 of breathing in patients with chronic obstructive pulmonary disease. *American Journal of*
 1355 *Respiratory and Critical Care Medicine* 151:1136–1142.
 1356 <https://doi.org/10.1164/AJRCCM.151.4.7697243>
- 1357 Gozzi-Silva SC, Teixeira FME, Duarte AJ da S, et al (2021) Immunomodulatory role of nutrients:
 1358 How can pulmonary dysfunctions improve? *Frontiers in Nutrition* 8:674258.
 1359 <https://doi.org/10.3389/FNUT.2021.674258>
- 1360 Grams ST, Ono LM, Noronha MA, et al (2012) Breathing exercises in upper abdominal surgery:
 1361 a systematic review and meta-analysis. *Revista Brasileira de Fisioterapia* 16:345–353.
 1362 <https://doi.org/10.1590/S1413-35552012005000052>
- 1363 Griffin JW, Hunter G, Ferguson D, Sillers MJ (1997) Physiologic effects of an external nasal
 1364 dilator. *The Laryngoscope* 107:1235–1238. [https://doi.org/10.1097/00005537-](https://doi.org/10.1097/00005537-199709000-00014)
 1365 [199709000-00014](https://doi.org/10.1097/00005537-199709000-00014)
- 1366 Gupta A, Sjoukes A, Richards D, et al (2011) Relationship between serum vitamin D, disease
 1367 severity, and airway remodeling in children with asthma. *American Journal of*
 1368 *Respiratory and Critical Care Medicine* 184:1342–1349.
 1369 <https://doi.org/10.1164/rccm.201107-1239OC>
- 1370 Gustafsson LE, Leone AM, Persson MG, et al (1991) Endogenous nitric oxide is present in the
 1371 exhaled air of rabbits, guinea pigs and humans. *Biochemical and Biophysical Research*
 1372 *Communications* 181:852–857. [https://doi.org/10.1016/0006-291X\(91\)91268-H](https://doi.org/10.1016/0006-291X(91)91268-H)

- 1373 HajBhanbari B, Yamabayashi C, Buna TR, et al (2013) Effects of respiratory muscle training on
 1374 performance in athletes: a systematic review with meta-analyses. *Journal of Strength*
 1375 *and Conditioning Research* 27:1643–1663.
 1376 <https://doi.org/10.1519/JSC.0b013e318269f73f>
- 1377 Hamasaki H (2020) Effects of diaphragmatic breathing on health: A narrative review. *Medicines*
 1378 7:1–19. <https://doi.org/10.3390/medicines7100065>
- 1379 Han YY, Forno E, Bacharier LB, et al (2021) Vitamin D supplementation, lung function and
 1380 asthma control in children with asthma and low vitamin D levels. *European Respiratory*
 1381 *Journal* 58:2100989. <https://doi.org/10.1183/13993003.00989-2021>
- 1382 Hao Q, Dong BR, Wu T (2015) Probiotics for preventing acute upper respiratory tract infections.
 1383 *The Cochrane Database of Systematic Reviews* CD006895.
 1384 <https://doi.org/10.1002/14651858.CD006895.PUB3>
- 1385 Harrison SE, Oliver SJ, Kashi DS, et al (2021) Influence of vitamin D supplementation by
 1386 simulated sunlight or oral D3 on respiratory infection during military training. *Medicine*
 1387 *and Science in Sports and Exercise* 53:1505–1516.
 1388 <https://doi.org/10.1249/MSS.0000000000002604>
- 1389 Hasani A, Pavia D, Toms N, et al (2003) Effect of aromatics on lung mucociliary clearance in
 1390 patients with chronic airways obstruction. *Journal of Alternative and Complementary*
 1391 *Medicine* 9:243–249. <https://doi.org/10.1089/10755530360623356>
- 1392 Haywood BA, Black KE, Baker D, et al (2014) Probiotic supplementation reduces the duration
 1393 and incidence of infections but not severity in elite rugby union players. *Journal of*
 1394 *science and medicine in sport* 17:356–360.
 1395 <https://doi.org/10.1016/J.JSAMS.2013.08.004>
- 1396 He Y, Zhao C, Liu Y (2021) Effects of respiratory muscle training on cough function in
 1397 neurological disorders: A systematic review with meta-analysis. *NeuroRehabilitation*
 1398 48:441–449. <https://doi.org/10.3233/NRE-210017>
- 1399 Heloneida de Araújo Morais A, de Souza Aquino J, Kelly da Silva-Maia J, et al (2021) Nutritional
 1400 status, diet and viral respiratory infections: perspectives for severe acute respiratory
 1401 syndrome coronavirus 2. *British Journal of Nutrition* 125:851–862.
 1402 <https://doi.org/10.1017/S0007114520003311>
- 1403 Hemilä H (2013) Vitamin C may alleviate exercise-induced bronchoconstriction: a meta-
 1404 analysis. *BMJ Open* 3:e002416. <https://doi.org/10.1136/BMJOPEN-2012-002416>
- 1405 Hemilä H, Chalker E (2013) Vitamin C for preventing and treating the common cold. *The*
 1406 *Cochrane Database of Systematic Reviews* 2013:CD000980.
 1407 <https://doi.org/10.1002/14651858.CD000980.PUB4>
- 1408 Hill C, Guarner F, Reid G, et al (2014) Expert consensus document. The International Scientific
 1409 Association for Probiotics and Prebiotics consensus statement on the scope and
 1410 appropriate use of the term probiotic. *Nature reviews: Gastroenterology & Hepatology*
 1411 11:506–514. <https://doi.org/10.1038/NRGASTRO.2014.66>

- 1412 Holland A, Hill CJ, Jones AY, McDonald CF (2012) Breathing exercises for chronic obstructive
 1413 pulmonary disease. *Cochrane Database of Systematic Reviews* 10:CD008250.
 1414 <https://doi.org/10.1002/14651858.CD008250.pub2>
- 1415 Hopkins SR, Dominelli PB, Davis CK, et al (2021) Face Masks and the Cardiorespiratory
 1416 Response to Physical Activity in Health and Disease. *Ann Am Thorac Soc* 18:399–407.
 1417 <https://doi.org/10.1513/AnnalsATS.202008-990CME>
- 1418 Hopkinson NS, Dayer MJ, Moxham J, Polkey MI (2010) Abdominal muscle fatigue following
 1419 exercise in chronic obstructive pulmonary disease. *Respiratory Research* 11:1–7.
 1420 <https://doi.org/10.1186/1465-9921-11-15>
- 1421 Hosseini B, Berthon BS, Wark P, Wood LG (2017) Effects of fruit and vegetable consumption on
 1422 risk of asthma, wheezing and immune responses: A systematic review and meta-
 1423 analysis. *Nutrients* 9:1–26. <https://doi.org/10.3390/nu9040341>
- 1424 Hostetter K, McClaran SR, Cox DG, Dallam G (2016) Triathlete adapts to breathing restricted to
 1425 the nasal passage without loss in $\dot{V}O_{2max}$ or $v\dot{V}O_{2max}$. *Journal of Sport and Human*
 1426 *Performance* 4:1–7. <https://doi.org/10.12922/jshp.v4i1.70>
- 1427 Illi SK, Held U, Frank I, Spengler CM (2012) Effect of respiratory muscle training on exercise
 1428 performance in healthy individuals. *Sports Medicine* 42:707–724.
 1429 <https://doi.org/10.1007/BF03262290>
- 1430 Jansang S, Mickleborough T, Suksom D (2016) Effects of pursed-lip breathing exercise using
 1431 windmill toy on lung function and respiratory muscle strength in the elderly. *Journal of*
 1432 *the Medical Association of Thailand* 99:1046–1051
- 1433 Janssens W, Mathieu C, Boonen S, Decramer M (2011) Vitamin D deficiency and chronic
 1434 obstructive pulmonary disease: a vicious circle. *Vitamins and Hormones* 86:379–399.
 1435 <https://doi.org/10.1016/B978-0-12-386960-9.00017-4>
- 1436 Jat KR, Goel N, Gupta N, et al (2021) Efficacy of vitamin D supplementation in asthmatic
 1437 children with vitamin D deficiency: A randomized controlled trial (ESDAC trial). *Pediatric*
 1438 *Allergy and Immunology* 32:479–488. <https://doi.org/10.1111/PAI.13415>
- 1439 Jensen D, Ofir D, O'Donnell DE (2009) Effects of pregnancy, obesity and aging on the intensity
 1440 of perceived breathlessness during exercise in healthy humans. *Respiratory physiology*
 1441 *& neurobiology* 167:87–100. <https://doi.org/10.1016/J.RESP.2009.01.011>
- 1442 Johnson BD, Babcock MA, Suman OE, Dempsey JA (1993) Exercise-induced diaphragm
 1443 fatigue in healthy humans. *Journal of Physiology* 460:385–405.
 1444 <https://doi.org/10.1113/jphysiol.1993.sp019477>
- 1445 Jolliffe DA, Camargo CA, Sluyter JD, et al (2021) Vitamin D supplementation to prevent acute
 1446 respiratory infections: a systematic review and meta-analysis of aggregate data from
 1447 randomised controlled trials. *The Lancet Diabetes and Endocrinology* 9:276–292.
 1448 [https://doi.org/10.1016/S2213-8587\(21\)00051-6](https://doi.org/10.1016/S2213-8587(21)00051-6)
- 1449 Jolliffe DA, Greenberg L, Hooper RL, et al (2017) Vitamin D supplementation to prevent asthma
 1450 exacerbations: a systematic review and meta-analysis of individual participant data. *The*

- 1451 Lancet Respiratory medicine 5:881–890. [https://doi.org/10.1016/S2213-2600\(17\)30306-](https://doi.org/10.1016/S2213-2600(17)30306-5)
1452 5
- 1453 Jolliffe DA, Greenberg L, Hooper RL, et al (2019) Vitamin D to prevent exacerbations of COPD:
1454 systematic review and meta-analysis of individual participant data from randomised
1455 controlled trials. *Thorax* 74:337–345. <https://doi.org/10.1136/THORAXJNL-2018-212092>
- 1456 Kacmarek RM, Ripple R, Cockrill BA, et al (1996) Inhaled nitric oxide. A bronchodilator in mild
1457 asthmatics with methacholine-induced bronchospasm. *American Journal of Respiratory*
1458 *and Critical Care Medicine* 153:128–135.
1459 <https://doi.org/10.1164/AJRCCM.153.1.8542105>
- 1460 Kanazaki M, Ebihara S (2017) Effect of the cooling sensation induced by olfactory stimulation by
1461 L-menthol on dyspnoea: A pilot study. *European Respiratory Journal* 49:1601823.
1462 <https://doi.org/10.1183/13993003.01823-2016>
- 1463 Kanazaki M, Terada K, Ebihara S (2021) L-menthol - a new treatment for breathlessness?
1464 *Current Opinion in Supportive and Palliative Care* 15:233–238.
1465 <https://doi.org/10.1097/SPC.0000000000000569>
- 1466 Kanazaki M, Terada K, Ebihara S (2020) Effect of olfactory stimulation by L-menthol on
1467 laboratory-induced dyspnea in COPD. *Chest* 157:1455–1465.
1468 <https://doi.org/10.1016/j.chest.2019.12.028>
- 1469 Kau AL, Ahern PP, Griffin NW, et al (2011) Human nutrition, the gut microbiome and the
1470 immune system. *Nature* 474:327–336. <https://doi.org/10.1038/NATURE10213>
- 1471 Knudson D (2009) Significant and meaningful effects in sports biomechanics research. *Sports*
1472 *Biomech* 8:96–104. <https://doi.org/10.1080/14763140802629966>
- 1473 Köteles F, Babulka P, Szemerszky R, et al (2018) Inhaled peppermint, rosemary and eucalyptus
1474 essential oils do not change spirometry in healthy individuals. *Physiology and Behavior*
1475 194:319–323. <https://doi.org/10.1016/j.physbeh.2018.06.022>
- 1476 Krakow B, Melendrez D, Sisley B, et al (2006) Nasal dilator strip therapy for chronic sleep-
1477 maintenance insomnia and symptoms of sleep-disordered breathing: a randomized
1478 controlled trial. *Sleep Breath* 10:16–28. <https://doi.org/10.1007/s11325-005-0037-7>
- 1479 Kumar A, Mastana SS, Lindley MR (2016) EPA/DHA dietary supplementation attenuates
1480 exercise-induced bronchoconstriction in physically active asthmatic males. *Cogent*
1481 *Medicine* 3:. <https://doi.org/10.1080/2331205X.2016.1172696>
- 1482 Kumar J, Kumar P, Goyal JP, et al (2021) Vitamin D supplementation in childhood asthma: a
1483 systematic review and meta-analysis of randomised controlled trials. *ERJ Open*
1484 *Research* 8:00662–02021. <https://doi.org/10.1183/23120541.00662-2021>
- 1485 Laborde S, Allen MS, Borges U, et al (2022) Effects of voluntary slow breathing on heart rate
1486 and heart rate variability: A systematic review and a meta-analysis. *Neuroscience and*
1487 *Biobehavioral Reviews* 138:104711. <https://doi.org/10.1016/J.NEUBIOREV.2022.104711>

- 1488 LaComb CO, Tandy RD, Ping Lee S, et al (2017) Oral versus nasal breathing during moderate
 1489 to high intensity submaximal aerobic exercise. *International Journal of Kinesiology and*
 1490 *Sports Science* 5:8. <https://doi.org/10.7575//aiac.ijkss.v.5n.1p.8>
- 1491 Langer D, Jacome C, Charususin N, et al (2013) Measurement validity of an electronic
 1492 inspiratory loading device during a loaded breathing task in patients with COPD.
 1493 *Respiratory medicine* 107:633–635. <https://doi.org/10.1016/J.RMED.2013.01.020>
- 1494 Lareau SC, Fahy B, Meek P (2020) Breathlessness – Shortness of breath. *American Journal of*
 1495 *Respiratory and Critical Care Medicine* 202:3–4
- 1496 Larsen KS, Skoffer B, Gregersen Oestergaard L, et al (2020) The effects of various respiratory
 1497 physiotherapies after lung resection: a systematic review. *Physiotherapy theory and*
 1498 *practice* 36:1201–1219. <https://doi.org/10.1080/09593985.2018.1564095>
- 1499 Lehouck A, Mathieu C, Carremans C, et al (2012) High doses of vitamin D to reduce
 1500 exacerbations in chronic obstructive pulmonary disease: a randomized trial. *Annals of*
 1501 *internal medicine* 156:105–120. <https://doi.org/10.7326/0003-4819-156-2-201201170-00004>
- 1503 Leith DE, Bradley M (1976) Ventilatory muscle strength and endurance training. *Journal of*
 1504 *applied physiology* 41:508–516. <https://doi.org/10.1152/JAPPL.1976.41.4.508>
- 1505 Lemoine C, Brigham E, Woo H, et al (2020) Relationship between omega-3 and omega-6 fatty
 1506 acid intake and chronic obstructive pulmonary disease morbidity. *Annals of the American*
 1507 *Thoracic Society* 17:378–381. <https://doi.org/10.1513/ANNALSATS.201910-740RL>
- 1508 Liu J, Dong YQ, Yin J, et al (2019) Meta-analysis of vitamin D and lung function in patients with
 1509 asthma. *Respiratory Research* 20:1–11. <https://doi.org/10.1186/S12931-019-1072-4>
- 1510 Lorca-Santiago J, Jiménez SL, Pareja-Galeano H, Lorenzo A (2020) Inspiratory muscle training
 1511 in intermittent sports modalities: A systematic review. *International Journal of*
 1512 *Environmental Research and Public Health* 17:4448.
 1513 <https://doi.org/10.3390/IJERPH17124448>
- 1514 Lu Y, Li P, Li N, et al (2020) Effects of home-based breathing exercises in subjects with COPD.
 1515 *Respiratory Care* 65:377–387. <https://doi.org/10.4187/respcare.07121>
- 1516 Lundberg JON, Settergren G, Gelinder S, et al (1996) Inhalation of nasally derived nitric oxide
 1517 modulates pulmonary function in humans. *Acta Physiologica Scandinavica* 158:343–
 1518 347. <https://doi.org/10.1046/j.1365-201X.1996.557321000.x>
- 1519 Luo C, Sun Y, Zeng Z, et al (2022) Vitamin D supplementation in pregnant women or infants for
 1520 preventing allergic diseases: a systematic review and meta-analysis of randomized
 1521 controlled trials. *Chinese medical journal* 135:276–284.
 1522 <https://doi.org/10.1097/CM9.0000000000001951>
- 1523 Macêdo TMF, Freitas DA, Chaves GSS, et al (2016) Breathing exercises for children with
 1524 asthma. *The Cochrane Database of Systematic Reviews* 2016:CD011017.
 1525 <https://doi.org/10.1002/14651858.CD011017>

- 1526 Mai X-M, Langhammer A, Camargo CA, Chen Y (2012) Original contribution serum 25-
 1527 hydroxyvitamin D levels and incident asthma in adults: The HUNT Study. *American*
 1528 *Journal of Epidemiology* 176:1169–1176. <https://doi.org/10.1093/aje/kws235>
- 1529 Mangla PK, Menon MPS (1981) Effect of nasal and oral breathing on exercise-induced asthma.
 1530 *Clinical and Experimental Allergy* 11:433–439. <https://doi.org/10.1111/J.1365-2222.1981.TB01616.X>
 1531
- 1532 Manifold J, Winnard A, Hume E, et al (2021) Inspiratory muscle training for improving
 1533 inspiratory muscle strength and functional capacity in older adults: a systematic review
 1534 and meta-analysis. *Age and Ageing* 50:716–724.
 1535 <https://doi.org/10.1093/AGEING/AFAA221>
- 1536 Manousaki D, Paternoster L, Standl M, et al (2017) Vitamin D levels and susceptibility to
 1537 asthma, elevated immunoglobulin E levels, and atopic dermatitis: A Mendelian
 1538 randomization study. *PLoS Medicine* 14:e1002294.
 1539 <https://doi.org/10.1371/journal.pmed.1002294>
- 1540 Marciniuk DD, Goodridge D, Hernandez P, et al (2011) Managing dyspnea in patients with
 1541 advanced chronic obstructive pulmonary disease: A Canadian Thoracic Society clinical
 1542 practice guideline. *Canadian Respiratory Journal* 18:69–78.
 1543 <https://doi.org/10.1155/2011/745047>
- 1544 Marotta N, Demeco A, Moggio L, et al (2020) Comparative effectiveness of breathing exercises
 1545 in patients with chronic obstructive pulmonary disease. *Complementary Therapies in*
 1546 *Clinical Practice* 41:101260. <https://doi.org/10.1016/j.ctcp.2020.101260>
- 1547 Marsland BJ, Trompette A, Gollwitzer ES (2015) The gut-lung axis in respiratory disease.
 1548 *Annals of the American Thoracic Society* 12:150–156.
 1549 <https://doi.org/10.1513/ANNALSATS.201503-133AW>
- 1550 Martineau AR, Jolliffe DA, Hooper RL, et al (2017) Vitamin D supplementation to prevent acute
 1551 respiratory tract infections: systematic review and meta-analysis of individual participant
 1552 data. *British Medical Journal* 356:i6583. <https://doi.org/10.1136/BMJ.i6583>
- 1553 Mason SA, Trewin AJ, Parker L, Wadley GD (2020) Antioxidant supplements and endurance
 1554 exercise: Current evidence and mechanistic insights. *Redox Biology* 35:101471.
 1555 <https://doi.org/10.1016/J.REDOX.2020.101471>
- 1556 McConnell AK (2012) CrossTalk opposing view: Respiratory muscle training does improve
 1557 exercise tolerance. *Journal of Physiology* 590:3397–3398.
 1558 <https://doi.org/10.1113/JPHYSIOL.2012.235572>
- 1559 McConnell AK, Lomax M (2006) The influence of inspiratory muscle work history and specific
 1560 inspiratory muscle training upon human limb muscle fatigue. *Journal of Physiology*
 1561 577:445–457. <https://doi.org/10.1113/jphysiol.2006.117614>
- 1562 McConnell AK, Romer LM (2004a) Dyspnoea in health and obstructive pulmonary disease: The
 1563 role of respiratory muscle function and training. *Sports Medicine* 34:117–132.
 1564 <https://doi.org/10.2165/00007256-200434020-00005>

- 1565 McConnell AK, Romer LM (2004b) Respiratory muscle training in healthy humans: Resolving
 1566 the controversy. *International Journal of Sports Medicine* 25:284–293.
 1567 <https://doi.org/10.1055/S-2004-815827/ID/38>
- 1568 McNarry MA, Berg RMG, Shelley J, et al (2022) Inspiratory muscle training enhances recovery
 1569 post COVID-19: A randomised controlled trial. *European Respiratory Journal* 2103101.
 1570 <https://doi.org/10.1183/13993003.03101-2021>
- 1571 Mendes LP, Moraes KS, Hoffman M, et al (2019) Effects of diaphragmatic breathing with and
 1572 without pursed-lips breathing in subjects with COPD. *Respiratory Care* 64:136–44.
 1573 <https://doi.org/10.4187/respcare.06319>
- 1574 Mickleborough TD, Lindley MR (2014) The effect of combining fish oil and vitamin C on airway
 1575 inflammation and hyperpnea-induced bronchoconstriction in asthma. *Journal of Allergy &*
 1576 *Therapy* 5:1–10. <https://doi.org/10.4172/2155-6121.1000184>
- 1577 Mickleborough TD, Lindley MR, Ionescu AA, Fly AD (2006) Protective effect of fish oil
 1578 supplementation on exercise-induced bronchoconstriction in asthma. *Chest* 129:39–49.
 1579 <https://doi.org/10.1378/CHEST.129.1.39>
- 1580 Mickleborough TD, Murray RL, Ionescu AA, Lindley MR (2003) Fish oil supplementation
 1581 reduces severity of exercise-induced bronchoconstriction in elite athletes. *American*
 1582 *Journal of Respiratory and Critical Care Medicine* 168:1181–1189.
 1583 <https://doi.org/10.1164/RCCM.200303-373OC>
- 1584 Millqvist E, Ternesten-Hasséus E, Bende M (2013) Inhalation of menthol reduces capsaicin
 1585 cough sensitivity and influences inspiratory flows in chronic cough. *Respiratory Medicine*
 1586 107:433–438. <https://doi.org/10.1016/j.rmed.2012.11.017>
- 1587 Molgat-Seon Y, Dominelli PB, Ramsook AH, et al (2018) The effects of age and sex on
 1588 mechanical ventilatory constraint and dyspnea during exercise in healthy humans.
 1589 *Journal of Applied Physiology* 124:1092–1106.
 1590 <https://doi.org/10.1152/jappphysiol.00608.2017>
- 1591 Morris GN, Rich GF (1997) Inhaled nitric oxide as a selective pulmonary vasodilator in clinical
 1592 anesthesia. *American Association of Nurse Anesthesiology* 65:59–67
- 1593 Morton AR, King K, Papalia S, et al (1995) Comparison of maximal oxygen consumption with
 1594 oral and nasal breathing. *Australian Journal of Science and Medicine in Sport* 27:51–55
- 1595 Mourgeon, Puybasset, Law-Koune, et al (1997) Inhaled nitric oxide in acute respiratory distress
 1596 syndrome with and without septic shock requiring norepinephrine administration: A dose-
 1597 response study. *Critical Care* 1:25–39. <https://doi.org/10.1186/cc4>
- 1598 Mündel T, Jones DA (2010) The effects of swilling an L(-)-menthol solution during exercise in
 1599 the heat. *European Journal of Applied Physiology* 109:59–65.
 1600 <https://doi.org/10.1007/S00421-009-1180-9>
- 1601 Naclerio RM, Pinto J, Assanasen P, Baroody FM (2007) Observations on the ability of the nose
 1602 to warm and humidify inspired air. *Rhinology* 45:102–11

- 1603 Nguyen JD, Duong H (2021) Pursed-lip breathing. StatPearls Publishing, Treasure Island,
1604 Florida, US
- 1605 Nield MA, Soo Hoo GW, Roper JM, Santiago S (2007) Efficacy of pursed-lips breathing: a
1606 breathing pattern retraining strategy for dyspnea reduction. *Journal of Cardiopulmonary*
1607 *Rehabilitation and Prevention* 27:237–244.
1608 <https://doi.org/10.1097/01.HCR.0000281770.82652.CB>
- 1609 Niinimaa V, Cole P, Mintz S, Shepard RJ (1980) The switching point from nasal to oronasal
1610 breathing. *Respiration Physiology* 42:61–71. [https://doi.org/10.1016/0034-](https://doi.org/10.1016/0034-5687(80)90104-8)
1611 [5687\(80\)90104-8](https://doi.org/10.1016/0034-5687(80)90104-8)
- 1612 Nishino T, Tagaito Y, Sakurai Y (1997) Nasal inhalation of l-menthol reduces respiratory
1613 discomfort associated with loaded breathing. *American Journal of Respiratory and*
1614 *Critical Care Medicine* 156:309–313. <https://doi.org/10.1164/ajrccm.156.1.9609059>
- 1615 Nitzan I, Mimouni FB, Nun A Bin, et al (2022) Vitamin D and asthma: A systematic review of
1616 clinical trials. *Current Nutrition Reports* 11:311–317. [https://doi.org/10.1007/S13668-022-](https://doi.org/10.1007/S13668-022-00411-6)
1617 [00411-6](https://doi.org/10.1007/S13668-022-00411-6)
- 1618 Noss MJ, Ciesla R, Shanga G (2019) Sleep quality and congestion with Breathe Right nasal
1619 strips: Two randomized controlled trials. *Advances in Therapy* 36:1975–1985.
1620 <https://doi.org/10.1007/s12325-019-01005-5>
- 1621 O’Kroy JA, James T, Miller JM, et al (2001) Effects of an external nasal dilator on the work of
1622 breathing during exercise. *Med Sci Sports Exerc* 33:454–8.
1623 <https://doi.org/10.1097/00005768-200103000-00019>
- 1624 O’Neill B, Mahon J Mac, Bradley J (2006) Short-burst oxygen therapy in chronic obstructive
1625 pulmonary disease. *Respiratory Medicine* 100:1129–1138.
1626 <https://doi.org/10.1016/J.RMED.2006.03.038>
- 1627 Parisien-La Salle S, Abel Rivest E, Boucher VG, et al (2019) Effects of pursed lip breathing on
1628 exercise capacity and dyspnea in patients with interstitial lung disease: A randomized,
1629 crossover study. *Journal of Cardiopulmonary Rehabilitation and Prevention* 39:112–117.
1630 <https://doi.org/10.1097/HCR.0000000000000387>
- 1631 Parvizian MK, Dhaliwal M, Li J, et al (2020) Relationship between dietary patterns and COPD: a
1632 systematic review and meta-analysis. *ERJ Open Research* 6:00168–02019.
1633 <https://doi.org/10.1183/23120541.00168-2019>
- 1634 Pasquina P, Tramèr MR, Granier JM, Walder B (2006) Respiratory physiotherapy to prevent
1635 pulmonary complications after abdominal surgery: a systematic review. *Chest* 130:1887–
1636 1899. <https://doi.org/10.1378/CHEST.130.6.1887>
- 1637 Patel MS, Hart N, Polkey MI (2012) CrossTalk proposal: training the respiratory muscles does
1638 not improve exercise tolerance. *Journal of physiology* 590:3393–3395.
1639 <https://doi.org/10.1113/JPHYSIOL.2012.235408>

- 1640 Pereira EJ, Sim L, Driver HS, et al (2013) The effect of inhaled menthol on upper airway
 1641 resistance in humans: A randomized controlled crossover study. *Canadian Respiratory*
 1642 *Journal* 20:e1-4. <https://doi.org/10.1155/2013/383019>
- 1643 Peters CM, Leahy MG, Hohert G, et al (2021) Airway luminal area and the resistive work of
 1644 breathing during exercise in healthy young females and males. *Journal of Applied*
 1645 *Physiology* 131:1750–1761. <https://doi.org/10.1152/JAPPLPHYSIOL.00418.2021>
- 1646 Pham H, Rahman A, Majidi A, et al (2019) Acute respiratory tract infection and 25-
 1647 hydroxyvitamin D concentration: A systematic review and meta-analysis. *Environmental*
 1648 *Research and Public Health* 16:3020. <https://doi.org/10.3390/ijerph16173020>
- 1649 Philips DB, Neder JA, Elbehairy AF, et al (2021) Qualitative components of dyspnea during
 1650 incremental exercise across the COPD continuum. *Medicine and Science in Sports and*
 1651 *Exercise* 53:2467–2476.
 1652 <https://doi.org/10.1249/MSS.0000000000002741>
- 1653 Porcari JP, Probst L, Forrester K, et al (2016) Effect of wearing the elevation training mask on
 1654 aerobic capacity, lung function, and hematological variables. *Journal of Sports Science*
 1655 *and Medicine* 15:375–386
- 1656 Rashidi K, Razi B, Darand M, et al (2021) Effect of probiotic fermented dairy products on
 1657 incidence of respiratory tract infections: a systematic review and meta-analysis of
 1658 randomized clinical trials. *Nutrition Journal* 20:61. [https://doi.org/10.1186/S12937-021-](https://doi.org/10.1186/S12937-021-00718-0)
 1659 [00718-0](https://doi.org/10.1186/S12937-021-00718-0)
- 1660 Ricciardolo FLM (2003) Multiple roles of nitric oxide in the airways. *Thorax* 58:175–182.
 1661 <https://doi.org/10.1136/thorax.58.2.175>
- 1662 Ries AL, Bauldoff GS, Carlin BW, et al (2007) Pulmonary rehabilitation: Joint ACCP/AACVPR
 1663 evidence-based clinical practice guidelines. *Chest* 131:S4–S42.
 1664 <https://doi.org/10.1378/CHEST.06-2418>
- 1665 Roberfroid M, Gibson GR, Hoyles L, et al (2010) Prebiotic effects: metabolic and health
 1666 benefits. *British Journal of Nutrition* 104:S1–S6.
 1667 <https://doi.org/10.1017/S0007114510003363>
- 1668 Rodrigues GD, Gurgel JL, Soares PP da S (2020) Inspiratory muscles contributions to postural
 1669 control in healthy older women. *Respiratory Physiology & Neurobiology* 281:103505.
 1670 <https://doi.org/10.1016/J.RESP.2020.103505>
- 1671 Romer LM, McConnell AK (2003) Specificity and reversibility of inspiratory muscle training.
 1672 *Medicine and Science in Sports and Exercise* 35:237–244.
 1673 <https://doi.org/10.1249/01.MSS.0000048642.58419.1E>
- 1674 Ruuskanen O, Luoto R, Valtonen M, et al (2022) Respiratory viral infections in athletes: Many
 1675 unanswered questions. *Sports Medicine* 52:2013–2021. [https://doi.org/10.1007/S40279-](https://doi.org/10.1007/S40279-022-01660-9)
 1676 [022-01660-9](https://doi.org/10.1007/S40279-022-01660-9)
- 1677 Sadan O, Shushan S, Eldar I, et al (2005) The effects of an external nasal dilator on labor.
 1678 *American Journal of Rhinology* 19:221–224

- 1679 Sagar S, Morgan ME, Chen S, et al (2014) Bifidobacterium breve and Lactobacillus rhamnosus
 1680 treatment is as effective as budesonide at reducing inflammation in a murine model for
 1681 chronic asthma. *Respiratory Research* 15:46. <https://doi.org/10.1186/1465-9921-15-46>
- 1682 Sandnes A, Andersen T, Clemm HH, et al (2022) Clinical responses following inspiratory
 1683 muscle training in exercise-induced laryngeal obstruction. *European Archives of Oto-*
 1684 *Rhino-Laryngology* 279:2511–2522. <https://doi.org/10.1007/S00405-021-07214-5>
- 1685 Santino TA, Chaves GSS, Freitas DA, et al (2020) Breathing exercises for adults with asthma.
 1686 *The Cochrane Database of Systematic Reviews* 2020:CD001277.
 1687 <https://doi.org/10.1002/14651858.CD001277.pub4>
- 1688 Schaeffer MR, McBride E, Mitchell RA, et al (2021) Effects of the Turbine™ on ventilatory and
 1689 sensory responses to incremental cycling. *Medicine and Science in Sports and Exercise*
 1690 53:192–199. <https://doi.org/10.1249/MSS.0000000000002427>
- 1691 Schultz K, Jelusic D, Wittmann M, et al (2018) Inspiratory muscle training does not improve
 1692 clinical outcomes in 3-week COPD rehabilitation: results from a randomised controlled
 1693 trial. *The European Respiratory Journal* 51:1702000.
 1694 <https://doi.org/10.1183/13993003.02000-2017>
- 1695 Seixas MB, Almeida LB, Trevizan PF, et al (2020) Effects of inspiratory muscle training in older
 1696 adults. *Respiratory Care* 65:535–544. <https://doi.org/10.4187/RESPCARE.06945>
- 1697 Settergren G, Angdin M, Astudillo R, et al (1998) Decreased pulmonary vascular resistance
 1698 during nasal breathing: modulation by endogenous nitric oxide from the paranasal
 1699 sinuses. *Acta Physiologica Scandinavica* 163:235–239. <https://doi.org/10.1046/j.1365-201x.1998.00352.x>
- 1701 Sheel AW, Boushel R, Dempsey JA (2018) Competition for blood flow distribution between
 1702 respiratory and locomotor muscles: Implications for muscle fatigue. *Journal of Applied*
 1703 *Physiology* 125:820–831. <https://doi.org/10.1152/jappphysiol.00189.2018>
- 1704 Shturman-Ellstein R, Zeballos RJ, Buckley JM, Souhrada JF (1978) The beneficial effect of
 1705 nasal breathing on exercise-induced bronchoconstriction. *American Review of*
 1706 *Respiratory Disease* 118:65–73. <https://doi.org/10.1164/ARRD.1978.118.1.65>
- 1707 Sluyter JD, Camargo CA, Waayer D, et al (2017) Effect of monthly, high-dose, long-term vitamin
 1708 D on lung function: A randomized controlled trial. *Nutrients* 9:1353.
 1709 <https://doi.org/10.3390/NU9121353>
- 1710 Spahija J, De Marchie M, Grassino A (2005) Effects of imposed pursed-lips breathing on
 1711 respiratory mechanics and dyspnea at rest and during exercise in COPD. *Chest*
 1712 128:640–650. <https://doi.org/10.1378/chest.128.2.640>
- 1713 Spruit MA, Singh SJ, Garvey C, et al (2013) An official American Thoracic Society/European
 1714 Respiratory Society statement: Key concepts and advances in pulmonary rehabilitation.
 1715 *American Journal of Respiratory and Critical Care Medicine* 188:e13–e64.
 1716 <https://doi.org/10.1164/RCCM.201309-1634ST>

- 1717 Stanford G, Ryan H, Solis-Moya A (2020) Respiratory muscle training for cystic fibrosis. The
 1718 Cochrane Database of Systematic Reviews 12:CD006112.
 1719 <https://doi.org/10.1002/14651858.CD006112.PUB5>
- 1720 Stoodley I, Garg M, Scott H, et al (2019) Higher omega-3 index is associated with better asthma
 1721 control and lower medication dose: A cross-sectional study. *Nutrients* 12:74.
 1722 <https://doi.org/10.3390/NU12010074>
- 1723 Strasser B, Geiger D, Schauer M, et al (2016) Probiotic supplements beneficially affect
 1724 tryptophan-kynurenine metabolism and reduce the incidence of upper respiratory tract
 1725 infections in trained athletes: A randomized, double-blinded, placebo-controlled trial.
 1726 *Nutrients* 8:752. <https://doi.org/10.3390/NU8110752>
- 1727 Tamaoki J, Chiyotani A, Sakai A, et al (1995) Effect of menthol vapour on airway
 1728 hyperresponsiveness in patients with mild asthma. *Respiratory Medicine* 89:503–504.
 1729 [https://doi.org/10.1016/0954-6111\(95\)90127-2](https://doi.org/10.1016/0954-6111(95)90127-2)
- 1730 Tanaka Y, Morikawa T, Honda Y (1988) An assessment of nasal functions in control of
 1731 breathing. *Journal of Applied Physiology* 65:1520–1524.
 1732 <https://doi.org/10.1152/jappl.1988.65.4.1520>
- 1733 Taylor BJ, How SC, Romer LM (2006) Exercise-induced abdominal muscle fatigue in healthy
 1734 humans. *Journal of Applied Physiology* 100:1554–1562.
 1735 <https://doi.org/10.1152/JAPPLPHYSIOL.01389.2005>
- 1736 Tecklenburg SL, Mickleborough TD, Fly AD, et al (2007) Ascorbic acid supplementation
 1737 attenuates exercise-induced bronchoconstriction in patients with asthma. *Respiratory*
 1738 *Medicine* 101:1770–1778. <https://doi.org/10.1016/J.RMED.2007.02.014>
- 1739 Tecklenburg-Lund S, Mickleborough TD, Turner LA, et al (2010) Randomized controlled trial of
 1740 fish oil and montelukast and their combination on airway inflammation and hyperpnea-
 1741 induced bronchoconstriction. *PloS one* 5:e13487.
 1742 <https://doi.org/10.1371/JOURNAL.PONE.0013487>
- 1743 Thien FC, Luca S De, Woods RK, Abramson MJ (2002) Dietary marine fatty acids (fish oil) for
 1744 asthma in adults and children. *The Cochrane Database of Systematic Reviews*
 1745 3:CD001283. <https://doi.org/10.1002/14651858.CD001283>
- 1746 Thoman RL, Stoker GL, Ross JC (1966) The efficacy of pursed-lips breathing in patients with
 1747 chronic obstructive pulmonary disease. *American Review of Respiratory Disease*
 1748 93:100–106. <https://doi.org/10.1164/arrd.1966.93.1.100>
- 1749 Thomas DQ, Larson BM, Rahija MR, McCaw ST (2001) Nasal strips do not affect
 1750 cardiorespiratory measures during recovery from anaerobic exercise. *Journal of Strength*
 1751 *and Conditioning Research* 15:341–343
- 1752 Tiep BL, Burns M, Kao D, et al (1986) Pursed lips breathing training using ear oximetry. *Chest*
 1753 90:218–21. <https://doi.org/10.1378/chest.90.2.218>

- 1754 Tiller NB, Campbell IG, Romer LM (2017) Influence of upper-body exercise on the fatigability of
 1755 human respiratory muscles. *Medicine and Science in Sports and Exercise* 49:1461–
 1756 1472. <https://doi.org/10.1249/MSS.0000000000001251>
- 1757 Tiller NB, Sullivan JP, Ekkekakis P (2022) Baseless claims and pseudoscience in health and
 1758 wellness: A call to action for the sports, exercise, and nutrition-science community.
 1759 *Sports Medicine* 2022 1–5. <https://doi.org/10.1007/S40279-022-01702-2>
- 1760 Törnberg DCF, Marteus H, Schedin U, et al (2002) Nasal and oral contribution to inhaled and
 1761 exhaled nitric oxide: A study in tracheotomized patients. *European Respiratory Journal*
 1762 19:859–864. <https://doi.org/10.1183/09031936.02.00273502>
- 1763 Torres-Castro R, Solis-Navarro L, Puppo H, et al (2022) Respiratory Muscle Training in Patients
 1764 with Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis. *Clocks &*
 1765 *sleep* 4:219–229. <https://doi.org/10.3390/CLOCKSSLEEP4020020>
- 1766 Tounsi B, Acheche A, Lelard T, et al (2021) Effects of specific inspiratory muscle training
 1767 combined with whole-body endurance training program on balance in COPD patients:
 1768 Randomized controlled trial. *PloS One* 16:e0257595.
 1769 <https://doi.org/10.1371/JOURNAL.PONE.0257595>
- 1770 Tran D, Munoz P, Lau EMT, et al (2021) Inspiratory Muscle Training Improves Inspiratory
 1771 Muscle Strength and Functional Exercise Capacity in Pulmonary Arterial Hypertension
 1772 and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Randomised Controlled
 1773 Study. *Heart Lung and Circulation* 30:388–395. <https://doi.org/10.1016/j.hlc.2020.06.006>
- 1774 Ubolnuar N, Tantisuwat A, Thaveeratitham P, et al (2019) Effects of breathing exercises in
 1775 patients with chronic obstructive pulmonary disease: systematic review and meta-
 1776 analysis. *Annals of Rehabilitation Medicine* 43:509–523.
 1777 <https://doi.org/10.5535/arm.2019.43.4.509>
- 1778 van der Schans CP, de Jong W, de Vries G, et al (1997) Respiratory muscle activity and
 1779 pulmonary function during acutely induced airways obstruction. *Physiotherapy Research*
 1780 *International* 2:167–177. <https://doi.org/10.1002/pri.98>
- 1781 Varraso R, Barr RG, Willett WC, et al (2015) Fish intake and risk of chronic obstructive
 1782 pulmonary disease in 2 large US cohorts. *American Journal of Clinical Nutrition*
 1783 101:354–361. <https://doi.org/10.3945/AJCN.114.094516>
- 1784 Venter C, Eyerich S, Sarin T, Klatt KC (2020) Nutrition and the immune system: A complicated
 1785 tango. *Nutrients* 12:818. <https://doi.org/10.3390/nu12030818>
- 1786 Verges S, Lenherr O, Haner AC, et al (2007) Increased fatigue resistance of respiratory
 1787 muscles during exercise after respiratory muscle endurance training. *American Journal*
 1788 *of Physiology - Regulatory Integrative and Comparative Physiology* 292:1246–1253.
 1789 <https://doi.org/10.1152/ajpregu.00409.2006>
- 1790 Verges S, Renggli AS, Notter DA, Spengler CM (2009) Effects of different respiratory muscle
 1791 training regimes on fatigue-related variables during volitional hyperpnoea. *Respiratory*
 1792 *physiology & neurobiology* 169:282–290. <https://doi.org/10.1016/J.RESP.2009.09.005>

- 1793 Verheijden KAT, Willemsen LEM, Braber S, et al (2016) The development of allergic
 1794 inflammation in a murine house dust mite asthma model is suppressed by synbiotic
 1795 mixtures of non-digestible oligosaccharides and *Bifidobacterium breve* M-16V. *European*
 1796 *Journal of Nutrition* 55:1141–1151. <https://doi.org/10.1007/S00394-015-0928-8>
- 1797 Verheijden KAT, Willemsen LEM, Braber S, et al (2015) Dietary galacto-oligosaccharides
 1798 prevent airway eosinophilia and hyperresponsiveness in a murine house dust mite-
 1799 induced asthma model. *Respiratory Research* 16:17. <https://doi.org/10.1186/S12931-015-0171-0>
 1800
- 1801 Vermoen CJ, Verbraak AF, Bogaard JM (1998) Effect of a nasal dilatator on nasal patency
 1802 during normal and forced nasal breathing. *International Journal of Sports Medicine*
 1803 19:109–13. <https://doi.org/10.1055/s-2007-971891>
- 1804 Vlieg-Boerstra B, Nicolette De Jong |, Meyer R, et al (2021) Nutrient supplementation for
 1805 prevention of viral respiratory tract infections in health subjects: A systematic review and
 1806 meta-analysis. *Allergy* 77:1373–1388. <https://doi.org/10.1111/all.15136>
- 1807 WADA (2022) Prohibited methods (prohibited at all times). *World Anti-Doping Code: Prohibited*
 1808 *List 2022* 13
- 1809 Walsh NP (2019) Nutrition and athlete immune health: New perspectives on an old paradigm.
 1810 *Sports medicine* 49:S153–S168. <https://doi.org/10.1007/S40279-019-01160-3>
- 1811 Wenzel M, Schönhofer B, Siemon K, Köhler D (1997) Nasal strips without effect on obstructive
 1812 sleep apnea and snoring. *Pneumologie* 51:1108–10
- 1813 West NP, Horn PL, Pyne DB, et al (2014) Probiotic supplementation for respiratory and
 1814 gastrointestinal illness symptoms in healthy physically active individuals. *Clinical*
 1815 *Nutrition* 33:581–587. <https://doi.org/10.1016/J.CLNU.2013.10.002>
- 1816 West NP, Pyne DB, Cripps AW, et al (2011) *Lactobacillus fermentum* (PCC®) supplementation
 1817 and gastrointestinal and respiratory-tract illness symptoms: a randomised control trial in
 1818 athletes. *Nutrition Journal* 10:30. <https://doi.org/10.1186/1475-2891-10-30>
- 1819 Williams NC, Hunter KA, Shaw DE, et al (2017) Comparable reductions in hyperpnoea-induced
 1820 bronchoconstriction and markers of airway inflammation after supplementation with 6.2
 1821 and 3.1 g/d of long-chain n-3 PUFA in adults with asthma. *British Journal of Nutrition*
 1822 117:1379–1389. <https://doi.org/10.1017/S0007114517001246>
- 1823 Williams NC, Johnson MA, Shaw DE, et al (2016) A prebiotic galactooligosaccharide mixture
 1824 reduces severity of hyperpnoea-induced bronchoconstriction and markers of airway
 1825 inflammation. *British Journal of Nutrition* 116:798–804.
 1826 <https://doi.org/10.1017/S0007114516002762>
- 1827 Witt JD, Guenette JA, Rupert JL, et al (2007) Inspiratory muscle training attenuates the human
 1828 respiratory muscle metaboreflex. *Journal of Physiology* 584:1019–1028.
 1829 <https://doi.org/10.1113/jphysiol.2007.140855>
- 1830 Woods A, Gustafson O, Williams M, Stiger R (2022) The effects of inspiratory muscle training
 1831 on inspiratory muscle strength, lung function and quality of life in adults with spinal cord

- 1832 injuries: a systematic review and Meta-analysis. *Disability and rehabilitation*.
 1833 <https://doi.org/10.1080/09638288.2022.2107085>
- 1834 World Health Organization (2022) Chronic obstructive pulmonary disease (COPD) [fact sheet].
 1835 [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd))
 1836 [disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)). Accessed 26 Sep 2022
- 1837 Worrapphan S, Thammata A, Chittawatanaarat K, et al (2020) Effects of inspiratory muscle
 1838 training and early mobilization on weaning of mechanical ventilation: A systematic review
 1839 and network meta-analysis. *Archives of Physical Medicine and Rehabilitation* 101:2002–
 1840 2014. <https://doi.org/10.1016/J.APMR.2020.07.004>
- 1841 Yagihara F, Lorenzi-Filho G, Santos-Silva R (2017) Nasal dilator strip is an effective placebo
 1842 intervention for severe obstructive sleep apnea. *Journal of Clinical Sleep Medicine*
 1843 13:215–221. <https://doi.org/10.5664/jcsm.6450>
- 1844 Yang H, Xun P, He K (2013) Fish and fish oil intake in relation to risk of asthma: A systematic
 1845 review and meta-analysis. *PloS One* 8:e80048.
 1846 <https://doi.org/10.1371/JOURNAL.PONE.0080048>
- 1847 Yang Y, Wei L, Wang S, et al (2022) The effects of pursed lip breathing combined with
 1848 diaphragmatic breathing on pulmonary function and exercise capacity in patients with
 1849 COPD: A systematic review and meta-analysis. *Physiother Theory and Practice* 38:847–
 1850 857. <https://doi.org/10.1080/09593985.2020.1805834>
- 1851 Yepes-Nuñez JJ, Brozek JL, Fiocchi A, et al (2018) Vitamin D supplementation in primary
 1852 allergy prevention: Systematic review of randomized and non-randomized studies.
 1853 *Allergy* 73:37–49. <https://doi.org/10.1111/all.13241>
- 1854 Yu H, Su X, Lei T, et al (2021) Effect of omega-3 fatty acids on chronic obstructive pulmonary
 1855 disease: A systematic review and meta-analysis of randomized controlled trials.
 1856 *International Journal of Chronic Obstructive Pulmonary Disease* 16:2677–2686.
 1857 <https://doi.org/10.2147/COPD.S331154>
- 1858 Zaccaro A, Piarulli A, Laurino M, et al (2018) How breath-control can change your life: A
 1859 systematic review on psycho-physiological correlates of slow breathing. *Frontiers in*
 1860 *Human Neuroscience* 12:1–16. <https://doi.org/10.3389/fnhum.2018.00353>
- 1861 Zaki S, Moiz JA, Mujaddadi A, et al (2022) Does inspiratory muscle training provide additional
 1862 benefits during pulmonary rehabilitation in people with interstitial lung disease? A
 1863 randomized control trial. *Physiotherapy theory and practice*.
 1864 <https://doi.org/10.1080/09593985.2021.2024311>
- 1865 Zemková E (2014) Significantly and practically meaningful differences in balance research: P
 1866 values and/or effect sizes? *Sports Med* 44:879–886. [https://doi.org/10.1007/s40279-014-](https://doi.org/10.1007/s40279-014-0185-7)
 1867 [0185-7](https://doi.org/10.1007/s40279-014-0185-7)
- 1868 Zhu M, Wang T, Wang C, Ji Y (2016) The association between vitamin D and COPD risk,
 1869 severity, and exacerbation: An updated systematic review and meta-analysis.
 1870 *International Journal of Chronic Obstructive Pulmonary Disease* 11:2597–2607.
 1871 <https://doi.org/10.2147/COPD.S101382>

1872 **FIGURES**

1873 **Figure. 1.** Primary outcomes from the literature on internal and external nasal dilators. ↑
 1874 = evidence of increase; ↓ = evidence of decrease; ↔ = evidence of no change; IND =
 1875 internal nasal dilator; END = external nasal dilator; OSA = obstructive sleep apnea;
 1876 $\dot{V}O_{2max}$ = maximal oxygen uptake; HR = heart rate; RPE = ratings of perceived exertion.

1877
 1878 **Figure. 2.** Primary outcomes from the literature on nasal breathing. ↑ = evidence of
 1879 increase; ↓ = evidence of decrease; ↔ = evidence of no change; NO = nitric oxide; $\dot{V}O_2$
 1880 = oxygen uptake; \dot{V}_E = minute ventilation; $\dot{V}_E/\dot{V}O_2$ = ventilatory equivalent for oxygen;
 1881 $\dot{V}_E/\dot{V}CO_2$ = ventilatory equivalent for carbon dioxide; $P_{ET}CO_2$ = end-tidal partial pressure
 1882 of carbon dioxide; f_R = respiratory frequency; V_T = tidal volume; $\dot{V}O_{2max}$ = maximal
 1883 oxygen uptake.

1884
 1885 **Figure. 3.** Primary outcomes from the literature on systematized breathing
 1886 interventions. ↑ = evidence of increase; ↓ = evidence of decrease; ↔ = evidence of no
 1887 change; FEV₁ = forced expiratory volume in 1 second; COPD = chronic obstructive
 1888 pulmonary disease; CO₂ = carbon dioxide.


1889
 1890 **Figure. 4.** Primary outcomes from the literature on respiratory muscle training
 1891 interventions. One of the putative mechanisms underpinning the effects of respiratory
 1892 muscle training on exercise tolerance and performance is a possible 'blunting' of the
 1893 respiratory muscle metaboreflex. ↑ = evidence of increase; ↓ = evidence of decrease; ↔
 1894 = evidence of no change. COPD = chronic obstructive pulmonary disease; O₂ = oxygen.

1895
 1896 **Figure. 5.** Primary outcomes from the literature on nutritional interventions. ↑ =
 1897 evidence of increase; ↓ = evidence of decrease; ↔ = evidence of no change. RTI =
 1898 respiratory tract infection; EIB = exercise-induced bronchoconstriction.

1899
 1900 **Figure. 6.** Primary outcomes from the literature on inhaled L-menthol. ↑ = evidence of
 1901 increase; ↓ = evidence of decrease; ↔ = evidence of no change. FEV₁ = forced


Science and pseudoscience in respiratory health

- 1902 expiratory volume in 1 second; FVC = forced vital capacity; PEF = peak expiratory flow;
1903 COPD = chronic obstructive pulmonary disease.
1904



1905
 1906
 1907


Fig. 1.



1908

1909 **Fig. 2.**


1910



1911

1912 **Fig. 3.**


1913



1914

1915 **Fig. 4.**


1916



1917

1918 **Fig. 5.**

1919



1920

1921 **Fig. 6.**

1922